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1.  Abstract 
Neisseria meningitidis colonizes the nasopharynx of humans and pathogenic strains can 
disseminate into the bloodstream causing septicemia and meningitis. Neisserial 
Heparin Binding Antigen (NHBA) and Neisserial Adhesin A (NadA) are part of a 
multicomponent vaccine against N. meningitidis serogroup B, called 4CMenB 
(Bexsero™).  
NHBA is a surface-exposed lipoprotein which is expressed by all N. meningitidis strains 
in different isoforms. NHBA harbors an arginine-rich motif through which it is able to 
bind heparin-like molecules, increasing adherence to host tissues and heparin-
mediated serum resistance. We determined that temperature controlled the expression 
of NHBA in all strains tested, regardless of the clonal complex or peptide isoform 
expressed. NHBA expression was significantly increased at 30-32°C compared to 37°C, 
the temperature standardly used for in vitro culturing. An increase in NHBA 
expression at lower temperatures was measurable both at protein and RNA levels and 
was also reflected by a higher surface exposure of this antigen. A detailed molecular 
analysis indicated that multiple molecular mechanisms are responsible for the 
thermoregulated NHBA expression. The comparison of RNA steady state levels in cells 
cultured at 30°C and 37°C demonstrated an increased RNA stability/translatability at 
lower temperatures. Furthermore, protein stability was also impacted resulting in 
higher NHBA stability at lower temperatures. Increased NHBA expression resulted in 
more efficient killing as shown by serum bactericidal assay (SBA). Mimicking the 
invasive condition, we investigated the NHBA expression in response to the presence 
of serum. We showed that the presence of human serum has contrasting effects on 
NHBA expression, resulting in transient up-regulation of NHBA at transcriptional 
level, however the protein is rapidly processed likely by complement proteases. We 
propose a model in which NHBA regulation in response to temperature downshift 
might reflect the bacterial adaptation during the initial step of host-bacterial interaction 
and might also explain higher susceptibility to anti-NHBA antibodies in the 
nasopharynx niche. On the other hand, the initial up-regulation and the high 
processing of NHBA might play a role during the first steps of invasive disease. All 
together these data describe the importance of NHBA both as virulence factor and as 
vaccine antigen during neisserial colonization and invasion. 
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In the second part of the thesis, we compared genetically engineered outer membrane 
vesicles and recombinant proteins, as delivery systems of protective antigen. Using 
NadA as model antigen, we determined that OMV overexpressing NadA produced by 
homologous (MenB) or heterologous (E.coli) bacterial strains, are able to elicit a higher 
functional antibody response respect to the recombinant protein per se, despite the 
comparable anti-NadA titres elicited. The differences in functionality might be due to 
different IgG subclasses distribution. Moreover, OMV overexpressing NadA are able to 
elicit antibodies that inhibit NadA-mediated adhesion on the host cells surface, in a 
much more efficient way respect to the recombinant protein formulation.   
These results indicate that the antigen delivered on OMV triggers a good functional 
immune response. This preliminary characterization supports the use of OMV as 
delivery systems for next generation vaccine design and remark the great potential of 
NadA as model antigen.   
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2.  Introduction 
2.1.  Meningococcal disease 
Invasive meningococcal disease is characterized by a rapid onset and progression to 
meningitis and/or sepsis which can lead to death within hours. The etiological agent of 
this devastating disease is Neisseria meningitidis, otherwise known as meningococcus. 
The first report of meningococcal disease is dated back to 1887 by Anton 
Weichselbaum, who described the meningococcal infection of the cerebrospinal fluid of 
a patient (Weichselbaum, A. 1887). Each year there are an estimated 1.2 million cases of 
invasive meningococcal disease and 135,000 deaths (WHO 2010). Despite the 
availability of antibiotic treatment, approximately 10 to 14% of people who contract 
meningococcal disease die, and the rate increases to 40-55% in the case of sepsis 
(Brandtzaeg, P. et al. 2005, Rosenstein, N.E. et al. 2001). Furthermore, approximately 11 
to 19% of individuals surviving the disease often suffer from permanent sequelae, 
including neuro-developmental deficits, hearing loss, ataxia, hemiplegia, seizures and 
limbs loss (Kaplan, S.L. et al. 2006, Rosenstein, N.E. et al. 2001, Thompson, M.J. et al. 
2006, WHO 2010).  
Multiple studies have demonstrated that carriage rates are very low in the first few 
years of life, but rise during adolescence, reaching peaks of 10-35%, and decreasing to 
less than 10% in older groups (Caugant, D.A. et al. 2007, Claus, H. et al. 2005). In 
contrast to carriage rates, meningococcal disease is rare, varying from 0.5 to 10 per 
100,000 persons; however, the incidence can rise above 1 per 1,000 persons during 
epidemics (Caugant, D.A. et al. 2009, Stephens, D.S. et al. 2007). Most cases of 
meningococcal disease occur in otherwise healthy individuals without identified risk 
factors and what determines the transition from colonization to invasive disease is not 
yet fully understood. However, certain biological, environmental and social factors 
have been associated with an increased risk of disease. Infants under one year of age 
have the highest risk of infection due to their immature immune systems (6.33-7.08 
cases per 100,000). Whereas, the peak observed in adolescents is largely due to 
increased carriage in this population (Cohn, A.C. et al. 2010). Several studies 
demonstrated that both host and pathogen factors influence the development of the 
disease, such as human genetic polymorphisms, impaired immune system, microbial 
virulence factors, as well as environmental conditions facilitating exposure and 
  
 
7 
 
acquisition, and naso- and oro-pharyngeal irritation caused by smoking and 
respiratory tract infection (Brigham, K.S. et al. 2009, Davila, S. et al. 2010, 
Goldschneider, I. et al. 1969, Harrison, L.H. 2006, Imrey, P.B. et al. 1995, Rosenstein, 
N.E. et al. 2001, Zuschneid, I. et al. 2008). The unspecific symptoms at the onset and the 
early stage of infection, like headache, fever and rash, can implicate an arduous 
diagnosis. Due to the rapid progression of this life-threatening pathology, vaccination 
represents the unique effective public health response. 
 
2.2.  Neisseria meningitidis: pathogen and pathogenesis 
N. meningitidis is a strictly human, Gram-negative β-proteobacterium member of the 
Neisseriaceae family. It is an aerobic, non-motile and non-sporulating diplococcus 
(Figure 2.1), usually encapsulated and piliated.  
 
 
Figure 2.1. Immuno-gold labelling and transmission electron microscopy of Neisseria 
meningitidis. Analysis of the strain was performed with antisera raised against the NadA 
adhesin. Scale bars: 200 nm (from (Pizza, M. et al. 2000) 
 
The envelope of N. meningitidis consists of the cytoplasmic membrane, the outer 
membrane (OM) and the periplasm between them, which contains a layer of 
peptidoglycan. The cytoplasmic membrane is a phospholipid bilayer, whereas the OM 
is composed of a phospholipidic inner leaflet and an outer leaflet of 
lipooligosaccharide (LOS). Some meningococcal strains have a polysaccharide capsule 
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attached to their OM and almost all pathogenic strains are encapsulated. Nevertheless, 
also non-encapsulated isolates have been recently associated to invasive disease 
(Johswich, K.O. et al. 2012). On the basis of the bacterial polysaccharide capsule, N. 
meningitidis can be classified into at least thirteen serogroups: A, B, C, E-29, H, I, K, L, 
W, X, Y, Z and 29E (Branham, S.E. 1953). Among them, six serogroups (A, B, C, X, Y 
and W) are responsible for more than 90% of meningococcal disease worldwide and 
are thus considered pathogenic (Boisier, P. et al. 2007, Frasch, C.E. 1989, Jarvis, G.A. et 
al. 1987, Stephens, D.S. et al. 2007). Meningococci are further classified into serotypes 
and serosubtypes according to antigenic differences in their major outer membrane 
proteins, PorA and PorB. However, the classification based on the serological 
characteristics of N. meningitidis is limited due to the high frequency of variation of 
OM-proteins, probably determined by a strong selective pressure. Hence, new DNA-
based methods for the characterization of meningococcal isolates have been developed, 
and the Multi Locus Sequence Typing (MLST) is now considered the gold standard for 
molecular typing and epidemiologic studies (Maiden, M.C. et al. 1998). This typing 
system relies on polymorphisms within seven housekeeping genes; each sequence for a 
given locus is screened for identity with already known sequences for that locus. If the 
sequence is different, it is considered to be a new allele and an identification number is 
assigned. Therefore, the combination of the seven allele numbers determines the allelic 
profile of the strain, and each different allelic profile is assigned as a sequence type 
(ST). Meningococci sharing at least four of the seven loci with a central ancestral 
genotype are grouped together into clonal complexes (CCs) (Urwin, R. et al. 2003). 
Through the employment of MLST it has been shown that the majority of strains 
associated with invasive disease belong to specific CCs (ST-1, ST-4, ST-5, ST-8, ST-11, 
ST-32, ST41/44 and ST-269), called hyper-invasive (Caugant, D.A. 2008, Maiden, M.C. 
2008). However, the reasons of this enhanced pathogenic phenotype are yet unknown. 
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The pathogenesis of N. meningitidis is a complex multi-stage process (Figure 2.2). 
 
 
 
Figure 2.2 Stages in the pathogenesis of Neisseria meningitidis. N. meningitidis may be 
acquired through the inhalation of respiratory droplets. The organism establishes intimate 
contact with non-ciliated mucosal epithelial cells of the upper respiratory tract, where it may 
enter the cells briefly before migrating back to the apical surfaces of the cells for transmission to 
a new host. Besides transcytosis, N. meningitidis can cross the epithelium either directly 
following damage to the monolayer integrity or through phagocytes in a ‘Trojan horse’ manner. 
In susceptible individuals, once inside the blood, N. meningitidis may survive, multiply rapidly 
and disseminate throughout the body and the brain. Meningococcal passage across the brain 
vascular endothelium (or the epithelium of the choroid plexus) may then occur, resulting in 
infection of the meninges and the cerebrospinal fluid (See text for details) (Virji, M. 2009). 
 
 
The human nasopharynx is the natural biological niche colonized by N. meningitidis 
and transmission to new hosts is facilitated through aerosol droplets (Caugant, D.A. 
and Maiden, M.C. 2009), as well as direct contact. Acquisition is generally 
asymptomatic, but infrequently may result in local inflammation, invasion of mucosal 
surfaces, access to the bloodstream and fulminant sepsis or focal infections such as 
meningitis (Stephens, D.S. et al.). Meningococcal disease usually occurs 1–14 days after 
acquisition of the pathogen (Rosenstein, N.E. et al. 2001), after which the carrier state 
may be established for a period that vary between days to months. From an 
evolutionary perspective, the interactions of meningococci and the human 
nasopharynx are key events. Meningococcal carriage and transmission, not disease, 
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determine the global variation and composition of the natural population of 
meningococci. 
Colonization is an essential but considerably challenging process in meningococcal 
survival, and therefore a prerequisite for strain carriage as well as for establishing 
invasive disease (Stephens, D.S.).  
Initially, N. meningitidis preferentially adheres to relatively non-ciliated or damaged 
areas of the epithelial barrier. Pili and outer membrane opacity proteins such as Opa 
and Opc play a major role for meningococcal adhesion to human cells (Hill, D.J. et al. 
2012, Kallstrom, H. et al. 2001). Upon contact with human cells, the meningococcus 
forms microcolonies and adheres using filamentous structures named type IV pili 
(T4P) which may recognize the host receptor CD46 (Kallstrom, H. et al. 2001), forming 
a layer tightly attached to host cells (Nassif, X. et al. 1997). After this step, the capsule, 
which masks the OM proteins via steric hindrance, is lost or down-regulated due to 
cell-contact induced repression (Deghmane, A.E. et al. 2002) or selection of low or no-
capsule expressing bacteria caused by phase variation (Hammerschmidt, S. et al. 1996). 
The absence of the capsule reveals a variety of redundant adhesins, which mediate a 
close adherence of the bacteria to host epithelial cells (Stephens, D.S. 2009). In fact, 
other minor adhesins such as Neisseria adhesin A (NadA) (Capecchi, B. et al. 2005), 
Neisseria hia/hsf homologue (NhhA) (Scarselli, M. et al. 2006), Adhesin complex 
protein (Acp) (Hung, M.C. et al. 2013), Adhesion and penetration protein (App) 
(Serruto, D. et al. 2003), Meningococcal serine protease A (MspA) (Turner, D.P. et al. 
2006) and Neisserial heparin binding antingen (NHBA) (Vacca, I. et al. 2016) have been 
shown to significantly contribute towards N. meningitidis colonization of the human 
nasopharynx. 
The interaction of bacterial opacity proteins, Opa and Opc, with CD66/CEACAMs and 
integrins respectively, on the surface of epithelial cells triggers meningococcal 
internalization (Gray-Owen, S.D. et al. 2006). Meningococci are capable of intracellular 
replication and this is in part due to iron acquisition mediated by specialized transport 
systems, such as the transferring binding protein (TbpAB), the lactoferrin binding 
protein (LbpAB), and the hemoglobin binding receptor (HmbR) (Perkins-Balding, D. et 
al. 2004). This intracellular lifestyle gives the bacteria the opportunity to evade the host 
immune response as well as to find new source of nutrients. Occasionally, bacteria can 
cross the mucosal epithelial barrier of susceptible individuals, either through 
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transcytosis or through phagocytes in a “Trojan horse” manner, or directly following 
damage to the monolayer integrity (Virji, M. 2009), and eventually enter the 
bloodstream. In healthy individuals, bacteria that cross the mucosal epithelium are 
eliminated by serum bactericidal activity. Nonetheless, survival within human blood 
relies upon different mechanisms and is dependent on their capability to evade the 
immune response and to acquire nutrients. Indeed, the up-regulation of capsule 
expression prevents antibodies and complement deposition (Uria, M.J. et al. 2008) 
hence inhibiting phagocytosis. Other strategies developed by the bacteria to evade the 
immune system are the recruitment of negative regulators of the complement cascades, 
such as Factor H (fH), which is bound by the Factor H binding protein (fHbp) (Madico, 
G. et al. 2006), or by the Neisserial surface protein A (NspA) (Lewis, L.A. et al. 2010), 
and by the Porin B (PorB) (Lewis, L.A. et al. 2013), or the recruitment of complement 
regulators, such as the C4-binding protein, which is bound by Porin A (PorA) (Jarva, 
H. et al. 2005). Once inside the bloodstream, meningococci can multiply slowly and 
eventually cross the blood-brain barrier, causing the infection of meninges and 
cerebrospinal fluid (Nassif, X. 2009). Otherwise, in case of rapid multiplication within 
the blood, the bacteria cause septicemia or meningococcemia (Rosenstein, N.E. et al. 
2001, Tinsley, C. et al. 2001). 
Overall, the onset of meningococcal disease can be seen as a failed relationship 
between the meningococcus and the host. While factors that trigger meningococcal 
entrance in the bloodstream are not yet fully understood, they are likely dependent on 
both the host and pathogen sides and include impairing of the integrity of the human 
nasopharyngeal mucosa, the lack of a protective immune response and microbial 
factors influencing virulence (Caugant, D.A. and Maiden, M.C. 2009, Stephens, D.S. et 
al. 2007). 
 
2.3.  Meningococcal virulence factors 
Within the host N. meningitidis colonizes and invades diverse sites which represent 
different niches with respect to nutrients, environmental factors and competing 
microorganisms. The pathogen is subjected to constant selective pressures and its 
ability to rapidly adapt its metabolism and cellular composition to environmental 
changes is essential for its survival (Hill, D.J. et al. 2010). Bacteria achieve adaptation to 
the environment either by changing their genotype (genome plasticity) or by transient 
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alterations in gene expression. These two mechanisms are complementary and both 
lead to phenotypic variations.  
The genome variability is also assured by the horizontal gene transfer that occurs with 
a relatively high frequency considering the high natural competence of meningococci. 
Instead, the genome plasticity is guaranteed by the abundance of mobile elements that 
represent the 10% of the entire genome (Parkhill, J. et al. 2000). Furthermore, other 
interesting phenomenon that significantly contributes to meningococcal genome 
plasticity is phase variation. It represents an adaptive process by which N. meningitidis 
undergoes stochastic, frequent and reversible phenotypic changes as consequence of 
genetic alterations in specific loci, altering mainly virulence-associated, surface-
exposed antigens such as outer-membrane proteins PorA, Opc, Opa, pili and specific 
adhesins, as well as LOS and capsule (Davidsen, T. et al. 2006, Feil, E.J. et al. 2001, 
Metruccio, M.M. et al. 2009, Moxon, E.R. et al. 1998). Meningococcal strains associated 
with disease have high frequency of phase variation, indicating that varying surface-
exposed components provides substantial benefits during transmission between hosts 
(Richardson, A.R. et al. 2002).  
Distinct from phase variation, antigenic variation is a mechanism of immune evasion 
where bacteria express different moieties of functionally conserved molecules that are 
antigenically distinct within a clonal population. This process is distinct from phase 
variation, as only one variant is expressed at any given time, although the cell still 
contains the genetic information to produce a whole range of antigenic variants. In the 
pathogenic Neisseria species, antigenic variation occurs in several surface components, 
including type IV pili, LOS and Opa proteins (Davidsen, T. and Tonjum, T. 2006).  
The virulence of N. meningitidis is influenced by multiple factors that are mainly 
located in the outer membrane (Figure 2.3).  
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Figure 1.3 Meningococcal cell compartments. Schematic representation of the different 
bacterial compartments and of the main components of the outer membrane, together with their 
known function (adapted from Rosenstein NE, 2001). 
 
The main virulence factor is the polysaccharidic capsule, which represents a barrier 
that protects the bacterium from the host innate and adaptive immune system 
(Schneider, Exley, Ram, Sim, & Tang, 2007; Vogel & Frosch, 1999). It also defends 
meningococcus from desiccation during airborne transmission between hosts (Virji, M. 
2009); (Romero, J.D. et al. 1997). Its expression is phase variable (Hammerschmidt, S. et 
al. 1996) and the switching of the capsule locus between strains confers a selective 
advantage to the bacterium for its evasion to opsonization or neutralization by natural 
or vaccine-induced anti-capsular antibodies (Swartley, J.S. et al. 1997). In 
meningococcus, LPS are referred to as lipooligosaccharide (LOS) because of the 
presence of repeating short saccharides instead of long-chain saccharides. LOS is the 
major constituent of the outer leaflet of the meningococcal outer membrane (OM), 
responsible for the physical integrity and proper functioning of the membrane and 
required for resistance of N. meningitidis to complement (Geoffroy, M.C. et al. 2003). 
LOS comprises an inner and outer oligosaccharide core attached to the lipid A portion 
that anchors the LOS in the outer leaflet of the OM. Lipid A is responsible for the 
toxicity of LOS due to its ability to bind to different Toll-like receptors on monocytes 
and on dendritic cells triggering the secretion of various inflammation mediators 
(Brandtzaeg, P. et al. 2001); (Braun, J.M. et al. 2002). Phase and antigenic variations lead 
to different saccharide chains altering dramatically the antigenic properties of LOS and 
enabling individual meningococci to display a repertoire of multiple LOS structures 
  
 
14 
 
simultaneously (Jennings, M.P. et al. 1999). Another group of virulence factors 
involved in the interface between the meningococcus and the host are pili. They are 
long filamentous structures consisting of protein subunits that extend from the 
bacterial surface beyond the capsule (Pinner, R.W. et al. 1991, Virji, M. et al. 1992). Pili 
represent the major contributor to the adhesive property of the capsule (Stephens, D.S. 
et al. 1981, Virji, M. et al. 1991) and in addition they are involved in the uptake of 
foreign DNA from the extracellular environment, hence increasing transformation 
frequency and consequently genetic adaptability (Helaine, S. et al. 2007). 
Furthermore, the presence of other OM-associated proteins is important in host cell 
interaction. The opacity proteins (Opa and Opc) are integral outer membrane proteins 
that mediate pathogen-host interaction, adhering to and invading of epithelial and 
endothelial cells (Virji, M. et al. 1992). A key role in the adhesion is carried out by 
adhesins, which are generally low expressed in vitro, but they might be upregulated in 
vivo. In fact, they may undergo to antigenic variation and/or phase variation, hence 
allowing the meningococcus to evade the immune system and adapt to different niches 
(Virji, M. 2009). The Neisserial adhesin A (NadA) is a surface-exposed member of the 
Oligomeric coiled-coil adhesin family of bacterial Trimeric Autotransporter adhesins 
(El Tahir, Y. et al. 2001, Helaine, S. et al. 2007). NadA mediates adhesion to and 
invasion of human epithelial cells (Capecchi, B. et al. 2005), suggesting its pivotal role 
in the adhesion to the naso- and oro-pharyngeal epithelia during meningococcal 
colonization of the human upper respiratory tract. Other adhesins have been reported 
to play a role in colonization and/or invasion. NHBA has been recently shown to 
participate during the colonization process by increasing adherence to host tissues by 
binding glycosaminoglycans (Vacca, I. et al. 2016), and mediating biofilm formation 
((Arenas, J. et al. 2013)). The Meningococcal surface fibril (Msf), previously termed 
Neisseria hia/hsf  homologue A (NhhA) (Peak, I.R. et al. 2000, Weynants, V.E. et al. 
2007), mediates adhesion to epithelial cells and to components of the extracellular 
matrix, even though at low levels (Scarselli, M. et al. 2006). Moreover, it has been 
shown its involvement in the immune system evasion. Msf binds to the activated form 
of Vitronectin and inhibits the terminal complement pathway (Griffiths, N.J. et al. 
2011), and its role in inhibiting phagocytosis, inducing macrophages apoptosis and 
protecting bacteria against complement-mediated killing has been suggested 
(Sjolinder, H. et al. 2008, Sjolinder, M. et al. 2012). Two homologous autotransporters, 
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the Adhesion penetration protein (App) and the Meningococcal serine protease A 
(MspA) are involved in the bacterial interaction to epithelial cells (Serruto, D. et al. 
2003, Turner, D.P. et al. 2006) and also in the apoptosis of dendritic cells (Khairalla, A.S. 
et al. 2015). Glycolipid adhesins such as members of the Multiple adhesin family (Maf) 
may contribute to the bacterial interaction with host cells (van Putten, J.P. et al. 1998). 
Interestingly they are found to be associated with genomic islands present only in 
pathogenic Neisseria species, both meningococcus and gonococcus (Jamet, A. et al. 
2015).  
The two porins PorA and PorB, are the most abundant proteins present in the 
meningococcal OM. They are composed of relatively conserved regions, which are 
predicted to form the β-barrel structure that spans through the membrane, alternated 
with variable regions, which should be surface-exposed, hence undergoing to a strong 
selective pressure. The formation of trimers creates the pore structure that allows the 
passage of small hydrophilic solutes necessary for the bacterial metabolism. Porins 
were shown to be interacting with several human cell types and proteins (Orihuela, 
C.J. et al. 2009); moreover, PorA elicits a protective immune response in humans 
(Holst, J. et al. 2009, Wedege, E. et al. 1998), while PorB might be involved in the 
immune system evasion by binding the human fH (hfH) (Lewis, L.A. et al. 2013). The 
regions of PorA that generate the immune response are loops 1 and 4, named VR1 and 
VR2, that are hyper variable among strains. OMV based vaccines, such as 4CMenB, use 
PorA as significant antigen generating bactericidal immune responses. However, due 
to the hyper variability of the immune-dominant regions, PorA-based vaccines provide 
protection only against strains expressing homologous PorA serosubtypes (see below). 
Furthermore, the genome of N. meningitidis contains a set of membrane-associated 
factors responsible for the host’s immune system evasion and hence for its virulence. 
As indicated by the elevated susceptibility to microbial, including meningococcal, 
infections exhibited by individuals with complement deficiencies (Figueroa, J. et al. 
1993). In order to escape from the innate immune system, N. meningitidis has evolved a 
plethora of mechanisms that target the complement cascades. As already introduced 
above, at least three meningococcal proteins have shown to bind the fH, fHbp (Madico, 
G. et al. 2006), NspA (Lewis, L.A. et al. 2010) and PorB (Lewis, L.A. et al. 2013). Strains 
lacking both fHbp and NspA were not able to bind fH and indeed were more 
susceptible to complement-dependent killing (Echenique-Rivera, H. et al. 2011, Lewis, 
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L.A. et al. 2010). In addition, the observed binding of heparin from the NHBA may 
increase bacterial serum resistance due to the potential interactions of heparin with fH 
(Serruto, D. et al. 2010). 
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2.4.  Anti-meningococcal vaccines  
Due to its rapid progression and the difficulties to diagnose it (Rosenstein, N.E. et al. 
2001, Thompson, M.J. et al. 2006), the most effective option to prevent meningococcal 
disease is vaccination. No broadly protective vaccine is currently available to provide 
protection against all serogroups of N. meningitidis. Different meningococcal vaccines 
have been developed against the distinct serogroups (Zahlanie, Y.C. et al. 2014). There 
are a number of polysaccharide and conjugate meningococcal vaccines in use against 
serogroups A, C, Y and W135. The tetravalent vaccine composed of purified capsular 
polysaccharides, although efficacious in adolescent and adults, is poorly immunogenic 
in infants and fails to induce immunological memory. However, when conjugated to a 
carrier protein, capsule polysaccharides show a greatly improved immunogenicity in 
young infants (Granoff, D.M. et al. 2007, Nassif, X. 2009, Virji, M. 2009). Monovalent, 
bivalent, and tetravalent polysaccharide conjugative vaccines are available and 
effective against meningococcal serogroups A, C, Y and W-135 (Zahlanie, Y.C. et al. 
2014); http://www.who.int/ith/vaccines/meningococcal/en/]. The first trials 
conducted in the United Kingdom with the meningococcus C conjugate showed a 
dramatic decline in the incidence of serogroup C disease in all age groups that received 
the vaccine (Borrow, R. et al. 2000, Miller, E. et al. 2001) with an efficacy of 97 and 92 
per cent for teenagers and toddlers, respectively (Ramsay, M.E. et al. 2001). 
In contrast, the group B capsule polysaccharide is not suitable as vaccine antigen. It 
consists of a homolinear polymer of α(2→8)N-acetyl neuraminic acid, also known as 
polysialic acid, which is structurally similar to the sialic acid found in human neural 
tissue, hence is poorly immunogenic in humans and may elicit auto-antibodies (Finne, 
J. et al. 1987, Finne, J. et al. 1983). Therefore, efforts to develop a vaccine against 
meningococcus serogroup B (MenB) focused mainly on non-capsular antigens, such as 
proteins or LOS. The principal challenge has been to identify surface-exposed non-
capsular antigens that are safe, antigenically conserved and that elicit a broad Serum 
Bactericidal Antibody (SBA) response. Licensed and promising group B vaccine 
approaches are discussed below.  
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2.4.1. Licensed vaccines against MenB  
Detergent-extracted OMV vaccines (dOMV) 
In order to control outbreaks caused by specific MenB strains vaccines composed of 
dOMV have been successfully employed in Norway (Fredriksen, J.H. et al. 1991), Cuba 
(Sierra, G.V. et al. 1991), Chile (Boslego, J. et al. 1995) and New Zealand (Oster, P. et al. 
2005).  The detergent treatment removes the toxic LOS, but it also extracts other 
desirable antigens such as lipoproteins. Consequently, the porin protein PorA results 
to be the immuno-dominant antigen (Martin, D.R. et al. 2006, Tappero, J.W. et al. 1999). 
Despite dOMV vaccines resulted to be safe and to induce good functional responses in 
humans, the immune response elicited is effective only against strains expressing the 
same PorA serosubtype, due to PorA antigenic variability (van der Ley, P. et al. 1991). 
Therefore, dOMV vaccines are well-suited to control local, clonal outbreaks but they do 
not confer broad protection. 
 
4CMenB 
The advent of the genomic era and the availability of whole genome sequences have 
contributed to radically change the approach to vaccine development. Indeed, the in 
silico approach named Reverse Vaccinology (RV) aims to identify surface-exposed 
non-capsular antigens that are antigenically conserved among strains and elicit a 
bactericidal serum response. This approach led to the development of the four 
component recombinant protein vaccine 4CMenB (Giuliani, M.M. et al. 2006, Giuliani, 
M.M. et al. 2010). 4CMenB contains five Genome-derived Neisseria Antigens (GNA) 
formulated together with the dOMV component from the NZ98/254 strain (Martin, 
D.R. et al. 2006). Based on their ability to induce broad protection three major antigens 
have been selected (Giuliani, M.M. et al. 2006): NadA (Capecchi, B. et al. 2005, 
Comanducci, M. et al. 2002) is present as single polypeptide, while fHbp (Beernink, 
P.T. et al. 2008, Masignani, V. et al. 2003) and NHBA (Serruto, D. et al. 2010, Welsch, 
J.A. et al. 2003) are fused to the conserved meningococcal gene products GNA2091 and 
GNA1030, respectively. The other two antigens, GNA2091 and GNA1030, are well 
conserved in N. meningitidis, but less functionally characterized than the other antigens 
(Bos, M.P. et al. 2014, Donnarumma, D. et al. 2015, Muzzi, A. et al. 2013). They were 
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included in the vaccine formulation since they increase immune responses to the main 
vaccine antigens when present as fusion proteins with the respect of the individual 
antigens (Giuliani, M.M. et al. 2006). 4CMenB was licensed in Europe in 2013 and in the 
U.S. in 2015, following its progression through clinical trials that have demonstrated its 
safety (Esposito, S. et al. 2014, Prymula, R. et al. 2014, Toneatto, D. et al. 2011) and its 
efficacy in inducing a protective immune response in infants, children, adolescents and 
adults against the majority of MenB strains (Gossger, N. et al. 2012, Kimura, A. et al. 
2011, McQuaid, F. et al. 2014, Read, R.C. et al. 2014, Santolaya, M.E. et al. 2012, Snape, 
M.D. et al. 2013, Vesikari, T. et al. 2013). 
 
 
Figure 2.4 Schematic representation of the 4CMenB vaccine antigens on the surface 
of N. meningitidis (from Serruto D, 2012). The different bacterial compartments (outer 
membrane, periplasmic space, cytoplasmic membrane) and the main antigens 
identified through reverse vaccinology approach (NHBA, fHbp and NadA) are 
depicted. Other components of the meningococcal membranes are also shown (pilus, 
polysaccharide capsule, lipooligosaccharide and integral inner and outer membrane 
proteins). 
 
 
Bivalent fHbp-based vaccine or Trumenba 
Trumenba was licensed in the U.S. in 2014 for a target population of adolescents and 
young adults. However, it is not suitable for use in infants considering that it consists 
of purified lipoproteins known as TLR-2 agonists (Richmond, P.C. et al. 2012). It is a 
recombinant protein-based vaccine composed of equal amounts of two variants, 
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subfamily A05/var3.45 and subfamily B01/var1.55, of lipidated fHbp (Fletcher, L.D. et 
al. 2004).  
 
2.4.2. Investigational MenB vaccines 
Recombinant protein vaccines 
Several protein antigens have been investigated for their protective ability for use in a 
MenB vaccine, among which NspA, TbpB, FetA, ZnuD and others (Halperin, S.A. et al. 
2007, Hubert, K. et al. 2013, West, D. et al. 2001). The main issue with all of these 
approaches was the limited cross protective potential of any one antigen. It was clear 
that a multivalent approach was needed to guarantee a wide protection. 
 
Native Outer Membrane Vesicles (nOMV) vaccines 
nOMV are spherical portions of the OM, ~20–250 nm in diameter, produced by Gram 
negative bacteria. They are spontaneously released during the active growth into the 
surrounding medium. These portions of the OM bud and detach from the cell, 
enclosing  many native bacterial antigens  and periplasmic constituents (Figure 2.5). 
The vesicles play diverse roles like delivery of virulence factors , modulation of the 
host immune system during pathogenesis, aid in nutrient acquisition, mediation of 
cellular communication, surface modifications and the elimination of undesired 
components that, ultimately, make them a transportable part of the bacterial arsenal 
and survival system (Collins, B.S. 2011, Kuehn, M.J. et al. 2005, Schwechheimer, C. et 
al. 2015).  
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Figure 2.5 Model of native Outer Membrane Vesicles (nOMV) biogenesis. NOMV vesicles are 
proteoliposomes consisting of OM phospholipids and LPS, a subset of OM proteins and 
periplasmic (luminal) proteins (Kuehn, M.J. and Kesty, N.C. 2005).  
 
nOMV represent an attractive vaccine platform mimicking the bacterial cell surface. 
Since nOMV do not undergo to a detergent extraction procedure, like dOMV do, they 
preserve high amounts of lipooligosaccharide (LOS) as well as protective lipoproteins 
which would otherwise be removed by the detergent. This was expected to improve 
immunogenicity and cross-protection provided but it raised safety concerns. 
Consequently, to prepare safe nOMV vaccines the strain must be genetically 
engineered to reduce the LOS reactogenicity. The acylation of lipid A molecule is 
responsible for its endotoxin activity and two mutations (lpxL1 and lpxL2), affecting 
the reduction of lipid A, have been successfully exploited (Bonvehi, P. et al. 2010, 
Keiser, P.B. et al. 2011, Keiser, P.B. et al. 2010, Koeberling, O. et al. 2011). The lpxL1 
gene, homologous to E.coli htrB, encodes for a late acyltransferase of lipid A 
biosynthesis. Its deletion lead to penta- instead hexa-acetylated molecules, resulting in 
lower endotoxin activity of LOS (van der Ley, P. et al. 2001). Instead the lpxL2 gene, 
homologous of E.coli lpxLM, encodes for a lauroyl acyltransferase. Its deletion leads to 
a tetra-acylated lipid A lacking both secondary lauroyl chains.  
nOMV vaccines prepared from wild-type strain were poorly immunogenic in mice 
(Koeberling, O. et al. 2008, Moe, G.R. et al. 2002). Koeberling and colleagues 
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demonstrated that the level of expression of a key antigen, as fHbp, was a critical 
parameter to elicit broad serum bactericidal responses (Koeberling, O. et al. 2011). The 
overexpression of some antigens (Keiser, P.B. et al. 2011) and the removal of the 
immunodominant PorA antigen (Bonvehi, P. et al. 2010) were two strategies tested in a 
phase I clinical trial.  In the first case, the nOMV vaccine resulted to be safe and 
immunogenic (Keiser, P.B. et al. 2011); nevertheless, the major contribution to 
bactericidal activities was from antibodies raised from LOS providing immunotype 
specific bactericidal responses. This result was suggested to be due to insufficient 
levels of the antigens over-expressed on the vesicles (Koeberling, O. et al. 2011). In the 
second case, PorA was deleted to avoid its immune-dominance. The prototype vaccine 
strain was also engineered to express a truncated form of LOS immunotype L3,7 that is 
the most common in invasive MenB strain (Scholten, R.J. et al. 1994). This OMV-based 
vaccine offered good safety but low immunogenicity in healthy young adults (Bonvehi, 
P. et al. 2010, Weynants, V. et al. 2009). 
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Chapter 1 
NHBA regulation and 
expression during 
colonization and invasion 
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Sensing the environment 
Colonization is an essential as well as a considerably challenging process in 
meningococcal survival, and therefore a prerequisite for strain carriage as well as for 
establishing invasive disease (Stephens, D.S. 2009). The nasopharyngeal epithelium is a 
complex ecological niche that poses several hurdles for bacterial colonization and 
survival.  Compounds such as mucus, antimicrobial peptides and immunoglobulins 
provide physical and biochemical host defenses (Laver, J.R. et al. 2015). Furthermore, 
this environment is deprived of nutrients such as iron, carbohydrates and oxygen 
essential for bacterial growth and N. meningitidis therefore needs to compete for these 
limited nutrients with the resident microflora. Taken together, these factors make de 
novo colonization and survival challenging. N. meningitidis is incredibly well adapted 
to this environment and has developed several mechanisms to control expression of 
adhesion molecules (Deghmane, A.E. et al. 2002) (Grifantini, R. et al. 2002, Hey, A. et al. 
2013), biofilm formation (Arenas, J. et al. 2013), iron acquisition (Larson, J.A. et al. 2002, 
Schryvers, A.B. et al. 1999), metabolism (Jamet, A. et al. 2009, Mendum, T.A. et al. 2011) 
(Laver, J.R. et al. 2015),  and immune evasion factors (Lomholt, H. et al. 1992, 
Yazdankhah, S.P. et al. 2004) . 
One of the key signals sensed by N. meningitidis to determine its environment and to 
induce the expression of either adhesion or immune evasion factors is temperature 
(Laver, J.R. et al. 2015). Temperatures within the upper respiratory tract are affected by 
the passage of air during respiration of the host, the precise anatomical location and 
the presence of local inflammation (Keck, T. et al. 2000, McFadden, E.R., Jr. et al. 1985) 
(Figure 2.6). These factors can result in an overall variability of temperature in this 
niche ranging from 25.3±2.1°C in the nasal vestibule to 33.9±1.5°C in the nasopharynx, 
generally being several degrees below core body temperature (Keck, T. et al. 2000). N. 
meningitidis has evolved to rapidly and efficiently adapt its metabolism to even minor 
temperature changes in the environment. During the development of invasive disease, 
N. meningitidis passes from the lower temperatures in the upper airway to the core 
body temperature of 37°C or higher with a febrile response to infection (Cabanac M. 
1990). Within the bloodstream although the increased temperature and the abundance 
of nutrients promote the fast growth of the bacterium, the presence of the complement 
cascade components, immunoglobulins and immune cells represent a big threat, 
meanwhile. Therefore a rapid adaptation to the new environment is required, in fact 
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approximately 30% of the genes in the genome are dramatically regulated on entry to 
whole human blood (Echenique-Rivera, H. et al. 2011), triggering an immune evasion 
response. Key antigens and virulence factors such as capsule biosynthesis (CssA), 
sialylation of LPS (Lst) and fHbp involved in immune evasion and in establishing 
invasive disease, show increased expression at 37°C relative to lower temperatures 
(Loh, E. et al. 2013, Loh, E. et al. 2016). However, the role of lower temperature on the 
expression of virulence factors has received considerably less attention. Recently, a 
comparative proteomic study showed that 375 proteins were differentially expressed 
between 32°C and 37°C (Lappann, M. et al. 2016).  
 
 
Figure 2.6 Within the host N. meningitidis encounters different niches. Temperature is one of 
the key signal sensed by N. meningitidis to determine its environment. The temperatures that N. 
meningitidis encounters during transmission, colonization and invasion are reported.  
 
Neisserial Heparing Binding Antigen (NHBA) 
NHBA is a surface exposed lipoprotein that is specific to Neisseria species. NHBA is 
one of the major antigens of the serogroup B meningococcal vaccine, 4CMenB (Serruto, 
D. et al. 2012), and induces antigen-specific bactericidal antibodies in both animals and 
humans (Serruto, D. et al. 2010); (Giuliani, M.M. et al. 2010). The nhba gene is 
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ubiquitous in meningococcal strains of all serogroups and it is also found in N. 
gonorrhoeae as well as in different commensal neisserial species (Bambini, S. et al. 2009); 
(Jacobsson, S. et al. 2006, Muzzi, A. et al. 2013). Analysis of gene sequences from 
genetically diverse serogroup B strains revealed the existence of more than 400 distinct 
peptides, which are associated with clonal complexes and sequence types 
(Comanducci, M. et al. 2002, Jacobsson, S. et al. 2006, Muzzi, A. et al. 2013). 
Considerable variation is observed at the level of primary amino acid sequence which 
ranges in length from approximately 430 to 500 residues (Figure 2.7). Most variability 
is observed at the level of the amino-terminal region, which is annotated as 
intrinsically unfolded by commonly used structure prediction algorithms (Vacca, I. 
2014). In contrast, the carboxyl-terminal region consists of a single 8-stranded anti-
parallel beta-barrel structure and is highly conserved (Esposito, V. et al. 2011).  
The two domains are linked through an arginine-rich motif which is responsible for 
NHBA binding to heparin in vitro and contributes to increased survival of the un-
capsulated N. meningitidis in human serum (Esposito, V. et al. 2011, Serruto, D. et al. 
2010). Conversely, it has been recently shown that NHBA plays an integral part in 
binding heparin sulfate proteoglycans on epithelial cells and thus directly mediates 
adhesion of N. meningitidis (Vacca, I. et al. 2016). Furthermore, the presence of this 
arginine-rich domain was implicated in DNA-binding and could therefore also play a 
role in the formation of neisserial microcolonies and biofilms (Arenas, J. et al. 2013). 
NHBA can be processed by the meningococcal protease NalP and human lactoferrin 
(hLf). Cleavage occurs either upstream and downstream of the NHBA Arg-rich region 
resulting in one of two possible cleavage fragments termed C2 and C1, respectively 
(Serruto, D. et al. 2010).  
It was also demonstrated that the C-terminal fragment (C2), released upon NalP 
proteolysis, alters endothelial cell permeability by inducing the internalization of the 
adherens junction protein VE-cadherin, which is in turn responsible for the endothelial 
leakage. Thus, the NHBA-derived fragment C2 might contribute to the extensive 
vascular leakage typically associated with meningococcal sepsis (Casellato, A. et al. 
2014). 
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Figure 2.7 NHBA protein schematic view and variability. NHBA protein sequence reflects a 
modular structural organization, where it is possible to recognize three main domains (A, B and 
C). The presence of an insertion sequence of 60 amino acids, present only in some of the NHBA 
peptides (Insertion IB), allows to discriminate between long or short isoforms. Functional sites 
are represented by the Arg-rich region (in brown), by the NalP cleavage site (in green) and by 
the human lactoferrin cleavage site (in grey). The C-term of the protein, corresponding to 
module C is highly conserved and is represented by a beta-barrel structure. The lower graph 
shows the percentage of amino acid conservation between the different peptides along the 
protein sequence (adapted from (Vacca, I. 2014)). 
 
 
The upstream regulatory region of the nhbA gene is characterized by the presence of 
the 150-bp Contact Regulatory Element of Neisseria (CREN) in strains, such as MC58, 
belonging to clonal complex ST-32. This regulatory element is specific to pathogenic 
Neisseria species and is involved in the induction of the downstream associated genes 
upon contact with target eukaryotic cells (Deghmane, A.E. et al. 2002). NHBA 
expression is known to be induced after incubation of bacteria with epithelial cells in 
the CREN-containing strain MC58, while its expression remains unaltered in the 
CREN-lacking strain 8013 (Deghmane, A.E. et al. 2003). It was therefore proposed that 
cell contact increased NHBA levels on meningococcal surface in the ST-32 invasive 
hypervirulent strains and that increased expression of nhba upon host contact might at 
least partially account for the hypervirulent phenotype of this clonal complex.  
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3.  Results 
3.1.  NHBA expression and surface exposure are temperature-dependent 
NHBA is an important virulence factor for N. meningitidis and it is also protective 
antigen able to elicit an immune response in preclinical and clinical trials (Serruto, D. et 
al. 2010). Therefore, understanding the mechanisms that drive NHBA regulation is an 
important goal to better understand N. meningitidis pathogenesis and vaccine induced 
response. We therefore investigated how physiologically relevant temperatures, which 
mimic the different stages of pathogenesis, may affect the expression levels of NHBA. 
Strains MC58, M11719 and 8047 were grown overnight on GC agar plates at 
physiologically relevant temperatures ranging from 28°C up to 40°C. We found that 
NHBA expression was thermoregulated in an inverse manner to fHbp, with higher 
expression at lower temperature. Western blot analysis showed that NHBA expression 
was at its highest level between 28°C and 30°C in all these strains and that its 
expression decreased markedly with increasing temperatures (Figure 3.1 A). In 
contrast, fHbp expression was highest at elevated temperatures and decreased with 
temperature reduction. In order to understand whether temperature regulation of 
NHBA was conserved among different N. meningitidis isolates, we expanded our 
analysis to a broader panel of strains belonging to different clonal complexes, carrying 
different variants and also long or short isoforms of NHBA (Figure 3.1 B and Table 3.1). 
NHBA expression levels were variable among the different strains and showed 
different processing patterns depending on the strain background and NHBA 
variant/isoform present (Table 3.1). Despite different variants and expression levels 
between the strains tested, all strains showed increased levels of NHBA at 30°C 
compared to 37°C. As NHBA is a surface exposed neisserial protein, we confirmed that 
increased expression levels of NHBA also resulted in increased levels of NHBA 
exposed on the bacterial cell surface using flow cytometry (Figure 3.1 C). 
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Figure 3.1 NHBA expression and surface exposure are increased at reduced temperatures. (A) 
The defined strains were grown overnight on GC agar plates at the indicated temperatures. 
Whole cell lysates were prepared and separated by SDS-PAGE prior to Western Blotting. The 
indicated proteins were detected using mouse-polyclonal antisera. Hfq served as loading 
control between different samples. In MC58 strain the full-length protein migrates with an 
apparent molecular weight of approximately 62 kDa, while other bands at approximately 49 
kDa results from the bacterial proteases’s processing (Serruto, D. et al. 2010). (B) The defined 
strains were grown in GC broth at 30°C or 37°C  until OD600  0.25. Whole cell lysates were 
prepared and separated by SDS-PAGE prior to Western Blotting.  Different strains express 
different variants and isoforms of NHBA (See table 3.1 for strains details), however the bands 
specificity is confirmed by the nhba deletion mutant (Δnhba) generated for each strain. (C) Flow 
cytometric analysis of strain MC58 showing surface exposure of NHBA at the indicated 
temperatures. 
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Strain Country 
of origin 
Year of 
isolation 
Capsular 
group 
Clonal 
complex 
NHBA 
peptide 
variant 
NHBA 
isoform 
M11205 USA 2003 B 41/44 p0001 Long 
M11822 USA 2004 B 41/44 p0001 Long 
NGH38 Norway 1988 B uaa p0002 Long 
MC58 UK 1985 B 32 p0003 Long 
M10935 USA 2003 B 35 p0058 Long 
M14933 USA 2006 B 32 p0003 Long 
M10713 USA 2003 B 41/44 p0010 Short 
M03279 USA 1997 B 41/44 p0011 Short 
N16/07 Norway 2007 B 41/44 p0029 Long 
M11204 USA 2003 B 41/44 p0029 Long 
M10282 USA 2003 B 41/44 p0002 Long 
M07-0240679 UK 2007 B 269 p0017 Short 
M11719 USA 2003 B 162 p0020 Short 
M16453 USA 2007 B 41/44 p0144 Short 
M18070 USA 2008 B 162 p0020 Short 
8047 USA 1978 B 11 p0020 Short 
 
Table 3.1 List of natural strains reported in Figure 3.1. Main characteristics are indicated. For 
each of them a nhba deletion mutant was generated. *Unassigned 
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3.2.  Mutations and deletions in the 5’UTR and 5’TR of nhba affect expression 
The nhba gene was originally annotated as NMB2132 according to its location within 
the genome sequence of the strain MC58 (Tettelin, H. et al. 2000). MC58 nhba locus 
schematic view (upper panel) and details of the intergenic region and the 5’TR of nhba 
(lower panel) are reported in Figure 3.2 A. The conservation of this region among all 
the Neisseria species present in the PubMLST database is also reported (mid panel). The 
region shows a very good conservation among 8373 Neisseria strains (green and 
greeny-brown bars). Red bars indicate the lack of conservation (5.8% strains) which 
corresponds to the CREN sequence,  specific for ST-32. 
Upstream and in the same orientation of nhba is located NMB2133. A Rho-independent 
terminator is predicted around 22 nucleotides downstream (Figure 3.2 A lower panel). 
qRTPCR experiments confirmed that no co-transcription is detectable among NMB2133 
and NMB2132 (data not shown). A putative promoter (Pnhba) was identified upstream 
the CREN sequence.  
The annotated translational start site is boxed in black and the ribosomal binding site is 
also indicated and underlined. However, in frame with the annotated one and just next 
to it, two more putative translational start sites were identified (boxed with dashed 
lines). Moreover, within the CREN sequence and still in frame with the annotated one, 
another putative translational start site (boxed in green) was identified, carrying also 
an alternative ribosomal binding site (underlined in green) (Deghmane, A.E. et al. 
2003). In order to investigate which one corresponds to the initiation of translation in 
correlation with temperature changes, a series of site-directed mutagenesis were 
performed (Figure 3.2 B). As shown by Western blot analysis, small deletions or single 
base mutations affecting these sites (Mut_1-4) led to decreased or abolished NHBA 
expression, without affecting thermoregulation (Figure 3.2 C left panel). We identified 
a T-rich region in the 5’TR of nhba, 20 nucleotides downstream to the putative 
translational start site. In silico secondary structure prediction of 5’UTR+50bp in the 
coding sequence suggested a direct interaction between the T-rich region and the 
ribosomal binding site (data not shown). Synonymous mutations in this region (Mut_5-
7) led to an overall decreased expression of NHBA, without affecting NHBA 
thermoregulation (Figure 3.2 C right panel). 
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Figure 3.2 Schematic representation of nhba locus in MC58 strain and site-directed 
mutagenesis. (A) Schematic representation of the nhba locus (upper panel). The conservation  of 
the indicated intergenic region obtained by multiple sequence alignments of 8373 Neisseria 
strains present in PubMLST database is shown (mid panel). Each bar represents the percentage 
of conservation of the corresponding nucleotide. Green bar = 100% identity; Greeny-brown bar 
< 100% identity; Red bar < 30% identity. The nucleotide sequence of the indicated region is 
reported (lower panel): the 3’ region of NMB2133 is boxed in dark grey and the 5’ region of nhba 
(NMB2132) is boxed in light grey. The nucleotides pairing in the stem region of the Rho-
independent terminator are underlined (dot line). In the intergenic region downstream of 
NMB2133, a putative promoter sequence was identified (Pnhba). The -35 and -10 elements of the 
Pnhba are indicated and the putative transcriptional start site is indicated and highlighted in 
bold. The contact regulatory element of Neisseria (CREN), a 150-bp sequence specific for 
pathogenic Neisseria species, is present in MC58 strain immediately upstream of the ribosomal-
binding site (Deghmane, A.E. et al. 2003) and is boxed in green. The ribosome binding sites are 
underlined and the translation start sites are boxed. (B) Schematic representation of site-
directed mutagenesis. Red dashes indicate nucleotides deletion, red nucleotides indicate  non-
synonymous mutations (Mut_3 and Mut_4) and synonymous mutations (Mut_5-Mut_7). (C) 
Mutant strains were grown overnight on GC agar plates at the indicated temperatures. Whole 
cell lysates were prepared and separated by SDS-PAGE prior to Western Blotting. The indicated 
proteins were detected using mouse-polyclonal antisera. The *a symbol indicates a non-specific 
band used as loading control between different samples. 
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3.3.  NHBA is expressed during the active growth 
Previous analysis only represented a single time point of NHBA expression levels 
during mid-exponential growth. In order to determine how NHBA expression 
progresses during the entire growth of N. meningitidis, we grew NGH38 strain at either 
30°C or 37°C in 50 ml of liquid culture. We took samples for RNA extraction and 
Western Blotting at various stages during the entire growth curve of the strain (Figure 
3.3). By culturing the strain in flasks, we were able to take samples every hour and 
follow the growth for ten hours (Figure 3.3 A). Both curves reached high OD600 values 
however, under these experimental conditions, bacteria grown at 30°C showed longer 
lag phase (T0-T4) and slightly lower OD600  values at the end of the growth, respect to 
those grown at 37°C. Firstly, we investigated the transcriptional profile of nhba, fHbp 
and adk during growth in liquid culture (Figure 3.3 B). We determined by qRT-PCR 
that nhba transcript was most abundant during active bacterial replication. Once 
bacteria entered stationary phase, transcription of nhba was almost abolished. During 
the active replication, nhba RNA steady state levels were higher at 30°C respect to 37°C. 
Conversely, fhbp transcript resulted to be slightly more abundant at 37°C respect to 
30°C, while no differences were observed for adk comparing the two temperatures. The 
nhba RNA steady state level expression profiles during the entire growth were 
confirmed also at protein level by Western blotting, showing that NHBA is most 
abundant during the active growth at both temperatures (Figure 3.3 C).The higher 
expression of NHBA also resulted in higher processing at 30°C. 
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Figure 3.3 NGH38 growth profiles and NHBA expression levels during the entire growth. (A) 
Growth profiles of NGH38 strain in 50 ml of MCDMI liquid medium at 30°C (blu line) or 37°C 
(red line). Bacteria were grown for 10 hours and RNA isolation and samples for Western blot 
analysis were collected every hour. (B) nhba, fHbp and adk RNA steady state levels were 
quantified by qRT-PCR and relative expression levels were determined normalizing to 16S-
rRNA. (C) Western blot analysis of NHBA on whole cell lysates collected at the indicated time 
points. In NGH38 strain the full-length protein migrate with an apparent molecular weight of 
approximately 62 kDa, while other bands at approximately 49 kDa results from the bacterial 
proteases’s processing (Serruto, D. et al. 2010). The *a symbol indicates a non-specific band used 
as loading control.  
 
 
Therefore we decided to compare more in details the expression of NHBA in response 
to temperature by using standard in vitro conditions. We grew MC58 strain at either 
30°C or 37°C in 7 ml liquid culture and took samples for RNA extraction and Western 
Blotting at various stages during the entire growth curve of the strain (Figure 3.4 A).  
Firstly, we investigated the transcriptional profile of nhba during growth in liquid 
culture (Figure 3.4 B). By qRT-PCR we confirmed that nhba transcript was most 
abundant during active bacterial replication. Once bacteria entered stationary phase, 
transcription of nhba was almost abolished (Figure 3.4 B). Although there was a trend 
for slightly increased nhba transcript levels at 30°C, these transcriptional differences 
were only significant in late exponential phase. We therefore next examined the NHBA 
protein expression profile at the same growth phase as the nhba transcript levels. In 
accordance with the data for the nhba transcript, we observed that NHBA level at each 
temperature were highest during exponential growth of the bacterium (Figure 3.4 C). 
As seen previously, NHBA protein levels in each growth phase were always higher at 
30°C relative to 37°C (Figure 3.4 C). However, although nhba transcript is barely 
detectable at stationary phase with no differences between the two temperatures, 
becomes evident that the protein is still abundant in bacteria cultured at 30°C. To 
quantify the differences in protein expression levels between the two temperatures 
tested, we used relative protein quantification (Figure 3.4 D). This analysis determined 
that the amount of NHBA at 30°C was approximately 3-5-fold higher than at 37°C.  
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Figure 3.4 NHBA is expressed during the exponential phase and its expression at 30°C is 
higher relative to 37°C at both RNA and protein levels. (A) Growth profiles of MC58 strain in 
GC liquid medium at 30°C (continuous line) or 37°C (dot line). Samples for western blot 
analysis and RNA isolation were collected at early exponential phase (OD600  ̴0.3), late 
exponential phase (OD600  ̴0.9) and at stationary phase (OD600  ̴1.1), as indicated by the star 
symbols. (B) nhba RNA steady state levels were quantified by qRT-PCR and relative expression 
levels were determined normalizing to 16S-rRNA. (C) Western blot analysis of NHBA on whole 
cell lysates collected at the indicated time points. (D) Relative protein quantification performed 
with ImageJ 1.6 software. In MC58 strain the full-length protein migrate with an apparent 
molecular weight of approximately 62 kDa, while other bands at approximately 49 kDa results 
from the bacterial proteases’s processing (Serruto, D. et al. 2010). The *a symbol indicates a non-
specific band used as loading control and for relative protein quantification. All the data 
represent the mean +/- SEM from three independent biological replicates and were analyzed by 
Two-way Anova followed by uncorrected Fisher’s LSD multiple comparison test (**** p<0.0001; 
*** p<0.001; ** p<0.01; * p<0.05; ns : not significant). 
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3.4.  NHBA thermoregulation is not driven by the nhba promoter 
To investigate the molecular mechanisms involved in NHBA thermoregulation a nhba 
deletion mutant (Δnhba) was generated in the MC58 strain background by replacement 
with an erythromycin antibiotic resistance cassette and different isogenic 
complementation mutants were generated. To test if the genomic context played a role 
in nhba regulation, the complete sequence, comprising the entire gene and the 
intergenic regulatory region, was inserted into the NMB1428-NMB1429 genomic locus, 
generating the Δnhba-C_nhba strain (Figure 3.5 A). As shown by Western blot analysis 
and qRT-PCR (Figure 3.6 A), the wild type and Δnhba-C_nhba strains showed the same 
expression and thermoregulation of nhba as the wild-type strain, indicating that 
placing the wild type sequence of nhba in another genomic locus does not affect nhba 
regulation in response to temperature changes at both RNA and protein level.  
In order to determine whether the nhba promoter was required for thermoregulation, 
we replaced the MC58 wild-type sequence with an IPTG-inducible Ptac promoter, 
immediately upstream of the CREN sequence (Figure 3.5 B), generating the Δnhba-
Ptac_nhba strain. We observed an IPTG dose-dependent increase of nhba expression at 
both RNA and protein level. However, using the same amount of IPTG for induction, 
we no longer observed any differences between the transcript levels at the two 
temperatures (Figure 3.6 B). Interestingly, we still observed clear thermoregulation of 
NHBA at protein level, albeit less pronounced than in the wild type strain.  
To determine whether regulatory elements in the nhba upstream intergenic region 
contributed to thermoregulation, we fused the full intergenic region comprising the 
promoter, the CREN sequence and the initial part of the coding sequence 
corresponding to the first 14 amino acids to a mCherry reporter gene (Figure 3.5 C), 
generating the Δnhba-Pwt_mCherry strain. As independent control, we also generated 
Δnhba-Ptac_mCherry strain, a reporter fusion under the control of the IPTG-inducible 
promoter (Figure 3.5 D). We then analyzed the expression of the reporter gene product 
by qRT-PCR and Western blotting of samples collected at either 30°C or 37°C (Figure 
3.6 C). The IPTG inducible promoter drove higher transcription of the downstream 
gene with respect to Pnhba promoter. However, no significant differences were 
observed at protein level. We observed no thermoregulation in either reporter fusion 
construct, both at RNA and at protein level, suggesting that the promoter on its own 
cannot account for the observed differences in expression at the two temperatures. All 
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together these results highlight that NHBA thermoregulation is at the post-
transcriptional level. 
 
 
 
Figure 3.5 Schematic representation of nhba mutants generated by ex-locus complementation. 
(A-D) In the MC58Δnhba strain background different mutants were generated by 
complementation in the NMB1428-1429 locus:  KanR-kanamycin resistance cassette; CmR-
chloramphenicol resistance cassette; LacI – LacI repressor gene; Ptac – IPTG inducible promoter; 
mCherry – mCherry reporter gene.  
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Figure 3.6 NHBA 
thermoregulation is at 
post-transcriptional 
level. (A-C) Wild type 
and recombinant strains 
were grown in GC liquid 
medium at 30°C or 37°C, 
with the indicated 
concentration of IPTG, 
where needed. NHBA 
and mCherry protein 
expression were assessed 
by western blotting by 
using polyclonal mouse 
antisera and monoclonal 
mouse antibody 
(ab167453, abcam), 
respectively (upper 
panel). nhba and mCherry 
RNA steady state levels 
were quantified by qRT-
PCR and relative 
expression levels were 
determined normalizing 
to 16S-rRNA (lower 
panel).  
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3.5.  Temperature affects nhba RNA half-life 
Transcription produces single-stranded RNA molecules that easily form intra- or 
intermolecular partially double-stranded RNAs, or associate with proteins, which may 
be used to regulate gene expression. To prevent or resolve kinetically trapped 
structures, cells use RNA chaperones that in most cases bind RNA non-specifically to 
help refold RNA or RNA–protein (RNP) complexes in ATP-independent or ATP-
dependent reactions (Herschlag, D. 1995); (Mohr, S. et al. 2002); (Rajkowitsch, L. et al. 
2007). The kinetic problem of RNA folding is dramatically aggravated at low 
temperatures. Few specific molecular mechanisms have been described to be involved 
in the cold shock response. CspA is the major regulator of the cold-shock response in 
E.coli, where the entire process of cold response is well documented. It is a RNA 
chaperone, able to bind both DNA and RNA, and its own regulation in response to 
temperature downshift is driven by a post-transcriptional mechanism which involves 
the 5’UTR region, resulting in higher transcript stability at low temperatures. The N. 
meningitidis homologue for cspA is NMB0838 and it resulted to be upregulated at 32°C 
in microarray analysis (data not shown). Another class of RNA binding proteins that 
accelerate structural rearrangements of RNA, particularly in the cold, are the DEAD-
box RNA helicases. By using ATP as substrate, they mediate RNA conformational 
changes, otherwise kinetically unstable (Iost, I. et al. 2013).  NMB1368 is a RNA helicase 
H present in N. meningitidis. Therefore, we decided to generate deletion mutants of 
NMB1368 and NMB0838 in MC58 strain background to investigate if this could have 
an effect on NHBA thermoregulation.  Mutant strains did not show alterations in 
thermoregulation, both by qRT-PCR and Western blotting (Figure 3.7), even if a 
slightly decrease in expression was observed in ΔNMB0838 mutant grown at 30°C.  
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Figure 3.7 Deletion of NMB1368 or NMB0838 genes did not affect NHBA thermoregulation. 
NMB1368 or NMB0838 genes were deleted in the MC58 wt strain background. Mutant strains 
were grown in GC broth at 30°C or 37°C  until OD600  0.5. Whole cell lysates and samples for 
RNA isolation were collected. (A) Whole cell lysates were prepared and separated by SDS-
PAGE prior to Western Blotting. The *a symbol indicates a non-specific band used as loading 
control and for relative protein quantification.  (B) nhba RNA steady state levels were quantified 
by qRT-PCR and relative expression levels were determined normalizing to 16S-rRNA. 
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We evaluated the nhba RNA decay after stopping active transcription by addition of 
rifampicin. The relative RNA amount was quantified by qRT-PCR (Figure 3.8). To 
obtain higher accuracy and reliability we used NGH38 as wild-type strain as overall 
nhba expression levels were higher compared to MC58. The transcript of nhba at 37°C 
showed a very short half-life and was rapidly degraded below the limit of detection 
(Figure 3.8). However, nhba transcript decay was found to be directly influenced by 
temperature, showing a shorter half-life at 37°C relative to 30°C 
 
 
Figure 3.8 The nhba transcript has a shortened half-life at elevated temperatures. Strain 
NGH38 was grown in GC broth until OD600 0.5 at the defined temperatures. RNA extracts were 
prepared at different time points after active transcription was stopped by adding rifampicin. 
nhba and 16s RNA abundance were measured by qRT-PCR and quantified relatively to the 
levels observed at the start of the experiment. Relative RNA quantity was calculated as 2-(Ct1-Ct0) 
and transformed as Y= log(Y). A linear regression was performed for each dataset and plotted 
as continuous lines. Data represent the mean from three independent biological replicates ± SD. 
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3.6.  NHBA protein shows higher stability at 30°C respect to 37°C 
Having determined that NHBA protein levels are strongly affected post-
transcriptionally, we wanted to investigate whether altered protein stability at different 
temperatures could account for the observed differences. We therefore grew the MC58 
wild type strain in GC broth at 30°C and 37°C to mid-exponential phase and stopped 
protein translation by adding spectinomycin. Each culture was then split and 
incubated at both 30°C and 37°C and samples for whole cell protein extraction were 
withdrawn at different time-points of treatment. NHBA accumulation upon protein 
translation arrest was analyzed by Western blots with representative results shown in   
Figure 3.9. At 30°C, the amount of NHBA full length protein appears the same for 45-
60 min treatment (Panel A, upper part), whereas treatment at 37 °C show no change for 
about 10 min treatment (Panel A, lower part). 
 Cells grown at 37 °C and treated with spectinomycin at 30 °C show a similar amount 
of NHBA for about 20 min treatment (Panel B, upper part), while treatment at 37 °C 
shows no changes for 10 min (Panel B, lower part). Overall, these data suggest that 
NHBA turnover is higher at 37°C and, accordingly, it appears stable at 30 °C. Thus, 
NHBA thermoregulation is additionally exerted by post-translational mechanisms. 
 
 
 
 
Figure 3.9 NHBA protein turnover is directly affected by temperature changes. (A-B) MC58 
wild type strain was grown in GC broth until OD600 0.5 at 30°C and 37°C. Whole cell extracts 
were prepared at different timepoints after the active translation was stopped by adding 
spectinomycin. Protein samples were separated by SDS-PAGE prior to Western Blotting using a 
anti-NHBA mouse polyclonal serum. The full length protein is shown. The *a symbol indicates 
a non-specific band used as loading control. 
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3.7.  NHBA expression levels correlate with susceptibility to complement-
mediated killing by anti-NHBA antibodies  
NHBA is one of the three major components of the 4CMen vaccine against serogroup B 
meningococcus and is a protective antigen that is able to elicit a robust immune 
response. Although NHBA is present in all neisserial species, we have shown that its 
expression is variable among strains and moreover is affected by several factors such 
as like growth phase and temperature changes. It is therefore paramount to 
understand how different NHBA expression levels, either through strain variation or 
triggered by different growth conditions affect the bacterium’s susceptibility to killing 
mediated by anti-NHBA antibodies.  
We therefore investigated whether the different NHBA expression levels at different 
temperatures could affect bacterial susceptibility to complement-mediated killing.  To 
address this hypothesis, we grew strain MC58 at both 30°C and 37°C and confirmed 
increased NHBA and decreased fHbp expression levels at 30°C compared to 37°C 
(Figure 3.10 A). Functional antigen should be exposed on the bacterial cell surface and 
we verified that altered antigen expression levels translated into altered surface 
exposure looking at NHBA, fHbp and cps surface exposure by flow cytometry (Figure 
3.10 B). Given these observations, we assessed the ability of immune serum raised 
against NHBA to kill N. meningitidis grown at the two different temperatures by 
determining their serum bactericidal titer (Figure 3.10 C). This assay is also called 
serum bactericidal assay (SBA) and was performed at both 30°C and 37°C. While clear 
differences in antigen expression were evident by Western blotting and flow cytometry 
analysis and trends of the SBA assays reflected these differences, we were unable to 
gain statistical significance due to the intrinsic variability of the experiment. We 
reasoned that altering the temperature would affect many different processes in the 
bacterial cell and confounding pleotropic effects would make it difficult to determine 
the precise impact of NHBA expression levels on serum bactericidal killing. For 
example, important virulence factors such as fHbp and the neisserial capsule also 
respond to temperature changes, but in the opposite way compared to NHBA (Figure 
3.10 B). These pleiotropic effects could then mask the role of NHBA in this assay 
making it impossible to extract how NHBA expression levels affect bacterial killing in 
this assay. 
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Figure 3.10 Temperature driven expression, surface exposure and susceptibility to 
complement-mediated killing. The MC58 wild type strain was grown at 30°C or 37°C in MH 
broth +0.25% glucose until OD600 0.25 was reached. Bacteria were collected and expression 
levels of NHBA and fHbp were determined by (A) Western blotting and surface exposure of the 
defined antigens was confirmed by (B) flow cytometry using polyclonal antisera. (C) Serum 
bactericidal titers were determined using baby rabbit complement as source of complement 
factors (rabbit SBA, rSBA). rSBA titers indicate the dilution of the α-NHBA mouse polyclonal 
serum, α-fHbp mouse polyclonal serum or α-cps mouse monoclonal antibody at which 50% of 
killing was reached. All the data are representative of three independent biological replicates. 
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In order to circumvent pleiotropic effect on bacterial expression of virulence factors 
other than NHBA, we generated a recombinant strain in which NHBA expression was 
under the control of an IPTG-inducible promoter (MC58 Δnhba-Ptac_nhba). This assay 
allowed us to perform the experiment under identical conditions while varying NHBA 
expression through addition of different IPTG concentrations. We confirmed protein 
expression and surface exposure of NHBA in these cultures using Western blotting and 
flow cytometry analysis (Figure 3.11 A and B, respectively).This then enabled us to 
extract the role of NHBA expression levels in the ability of anti-NHBA antiserum from 
mice to mediate complement-dependent killing through the rSBA (Figure 3.11 C). We 
observed that rSBA titers correlated directly with NHBA expression levels, as 
confirmed by statistical analysis. 
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Figure 3.11 Correlation between NHBA expression, surface exposure and susceptibility to complement-mediated killing by anti-NHBA antibodies. MC58 
Δnhba, wild type and Δnhba-Ptac_nhba strains were grown in MH broth +0.25% glucose until OD600 0.25 at 30°C or 37°C as indicated. IPTG was added, where 
needed, at the indicated final concentrations. Bacteria were collected to perform (A) Western blotting, (B) flow cytometry analysis and (C) serum bactericidal assay. 
The relative quantification obtained by (A) densitometry analysis and (B) FACS geometric mean calculation were estimated. All the data represent the mean +/- SD 
from three independent biological replicates and a linear regression was performed on each dataset (black lines indicate the linear fit, dot lines indicate the 95% CI). 
A Pearson correlation test was used to assess the goodness of correlation between the three different datasets (Densitometry/SBA titers: Pearson r = 0,962; P=0.009. 
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Densitometry/FACS GeoMean: Pearson r = 0,972; P=0.006; FACS GeoMean/SBA titers: Pearson r = 0,925; P=0.008). Western blotting relative quantification of 0.050 
mM IPTG samples were not taken into account for the linear regression as these were found to be out of the linearity range of the assay  
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3.8.  NHBA regulation during invasion 
It has been previously shown that NHBA can be processed by the meningococcal 
protease NalP and human lactoferrin. Cleavage occurs either upstream and 
downstream of the NHBA Arg-rich region resulting in one of two possible cleavage 
fragments termed C2 and C1, respectively (Serruto, D. et al. 2010). To mimic the 
invasive condition MC58 and NGH38 wild type strains were grown until early 
exponential phase and then incubated at 37°C in presence of 25% of human serum 
during a time course, up to 2 hours (Figure 3.12 A and B). After 15 minutes of serum 
incubation NHBA was induced and strongly processed in both strains. In fact, despite 
the appearance of the lower bands typical of the N terminal portion of NHBA after 
cleavage of the protein, the band corresponding to the full length protein appeared to 
retain the same intensity or even more suggesting induction of the full length NHBA as 
well as concomitant processing. Within the blood there is an abundance of components 
with proteolytic activity, so it is not surprising to see an increase in cleavage. The 
induction and the processing proceed for the first 30 minutes after which, under these 
in vitro conditions, the overall amount of the full length protein decreases strongly 
with different kinetics among the two strains. Not only they express different levels of 
nhba, moreover the different background is somehow responsible for different stability 
of the protein. Therefore, while in MC58 the band corresponding to the full length 
protein almost disappeared after 2 hours of incubation, in NGH38 strain it is only 
slightly reduced. The induction is confirmed also at the transcriptional level, as shown 
by qRT-PCR (Figure 3.12 B). Following serum incubation a transient induction of 
transcriptional induction was immediately registered, with maximal levels after 30 
minutes. 
We assessed the serum dose-response by incubating both strains at 37°C for 30 minutes 
in a dose-range of human serum. Even at the lowest concentration of serum, cleavage 
of NHBA is observed in both strains. A proportional increase in the processed band, 
correlated with serum dose, was clearly observed in MC58 strain and less apparent in 
NGH38 strain (Figure 3.12 C). Although serum induction is confirmed at the RNA level 
(Figure 3.12 D), a direct dose-response correlation was not observed. This is maybe due 
to pleiotropic effects of serum bactericidal killing on total mRNA levels. Finally, we 
compared the effects of different sources of serum on NHBA expression. Both 
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induction and cleavage events are triggered by mouse, human and baby rabbit serum 
sources, even to slightly different extent (Figure 3.12 E and F). 
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Figure 3.12 NHBA protein and RNA expression levels after serum incubation: time course, 
dose-response and different sources of serum. (A) MC58 wt and NGH38 wt strains were 
grown at 37°C in MH broth +0.25% glucose until OD600 0.25 was reached. Bacteria were 
collected and incubated at 37°C in DPBS++ with 0,1% glucose, +1%BSA and 25% of human 
serum. Whole cell lysates were prepared at the indicated timepoints. Protein samples were 
separated by SDS Page prior to Western blotting. (B) RNA extracts (NGH38 wt strain) at the 
indicated time points were prepared.  nhba RNA steady state levels were quantified by qRT-
PCR and relative expression levels were determined normalizing to 16S-rRNA (C-D) MC58 wt 
and NGH38 wt strains were grown at 37°C in MH broth +0.25% glucose until OD600 0.25 was 
reached. Bacteria were collected and incubated for 30 min at 37°C in DPBS++ with 0,1% glucose, 
+1%BSA and different concentration of human serum. (C) Whole cell lysates were prepared and 
analysed by Western blotting. (D) RNA extracts were performed in parallel and nhba RNA 
steady state level was determined by qRT-PCR (E-F) MC58 wt and NGH38 wt strains were 
grown at 37°C in MH broth +0.25% glucose until OD600 0.25 was reached. Bacteria were 
collected and incubated for 30 min at 37°C in DPBS++ with 0,1% glucose, +1%BSA, in presence 
or not of 25% of human serum (hSer), mouse serum (mSer) or baby rabbit complement (BRC). 
Western blotting and qRT-PCR analysis were performed. The *a symbol indicates a non-specific 
band used as loading control between different samples. 
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3.9.  NHBA cleavage does not affect NHBA-mediated killing susceptibility 
Previously, it was shown that mutation of the arginine stretch abrogates cleavage by 
lactoferrin but was not sufficient to block NalP cleavage (Serruto, D. et al. 2010). NalP 
cleaves at serine residue directly upstream of the Arg-rich region. Mutation of this 
serine alone into an alanine by site directed mutagenesis did not abrogate NalP 
cleavage (data not shown). At least eleven putative NalP target domains have been 
identified through a bioinformatics approach (Muzzi, A. et al. 2013, Serruto, D. et al. 
2010) within different NHBA peptides. In particular it was observed that NHBA 
peptide p5 seems to lack the residues which are usually recognized by NalP (Table 3.2) 
and this peptide is resistant to NalP cleavage (Vacca, I. 2014).  
 
   
NalP target 
domain name 
NalP target domain 
sequence 
NHBA variant and 
isoform 
NalP_td_1 YKPKP - - TSFARFRRSA p0001 (Long) 
  
p0002 (Long) 
  
p0003 (Long) 
NalP_td_2 YKDKS - - TSSAQFRRSA p0017 (Short) 
  
p0018 (Short) 
NalP_td_5 YKDKSASSSFARFRRSA p0021 (Short) 
NalP_td_6 YKDKSASSSSARFRRSA p0020 (Short) 
  
p0029 (Long) 
NalP_td_8 YKPKT - - TSSARFRRSA p0010 (Short) 
NalP_td_11 YTDKP- - - - - - - -PTRSA p0005 (Long) 
 
Table 3.2 Analysis of NalP target domain sequences. Six different classes of NalP target 
domains were observed for NHBA peptides p1, p2, p3, p5, p10, p17, p18, p20, p21, p29. These 
classes are indicated in the first column of the table. The last column shows an example of 
NHBA peptides associated to the different NalP target domains. (Adapted from (Vacca, I. 2014)) 
 
Based on this observation we generated a MC58 recombinant strain called ΔTSFAmRR, 
expressing a NHBA protein in which we combined the deletion of the NalP target 
domain sequence TSFA with the mutation of the Arg-rich domain in a Gly-stretch 
(Figure 3.13 A). Respect to the wild type, ΔTSFAmRR strain resulted to be fully 
resistant to cleavage by NalP and other proteases, even in presence of serum (Figure 
3.13 B). When testing the thermoregulation of NHBA expressed in the mutant strain, 
even if less pronounced, differences in protein amount at 30°C and 37°C were still 
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visible. We tested whether the resistance to cleavage would affect the susceptibility of 
MC58 to anti-NHBA antibodies in a serum bactericidal assay. The strains were grown 
for the bactericidal assay at 30 and 37°C. A moderate difference of one titre, as shown 
previously (Figure 3.10 C), was observed in response to temperature for both the wild 
type and the ΔTSFAmRR strains (Figure 3.13 C). However, no differences were 
observed in bactericidal titres between the wild type and the recombinant strain by 
using polyclonal mouse serum against the full length protein indicating that the 
cleavage of NHBA does not affect the overall bactericidal susceptibility of the strain to 
anti-NHBA antibodies. By using a polyclonal mouse serum specific for the C2 
fragment of the protein, only the ΔTSFAmRR strain at 30°C showed a barely positive 
SBA titer.  
 
 
     
 
MC58 wt  
30°C 
MC58 wt  
37°C 
ΔTSFAmRR 
30°C 
ΔTSFAmRR 
37°C 
α-NHBA 
FL 
2048 1024 2048 1024 
α-NHBA 
C2 
<4 <4 8 <4 
 
  
  
Figure 3.13 Expression and killing susceptibility of MC58 wild type and ΔTSFAmRR mutant 
strains. (A) ΔTSFAmRR mutant was generated by two step of site-directed mutagenesis within 
the nhba sequence. The mutated nhba sequence was used for in locus complementation in the 
MC58Δnhba strain background. The wild type and mutant strains were grown in in MH broth 
+0.25% glucose until an OD600 of 0.25 at 30°C or 37°C, as indicated. Bacteria were collected 
before and following the incubation in presence of 25% of baby rabbit complement at 37°C for 1 
hour and total protein extracts were performed. (B) Western blotting and (C) serum bactericidal 
assay. The rSBA was performed at the indicated temperatures, using two polyclonal mouse 
sera, one specific for the C-terminal domain of NHBA (α-NHBA C2), and one able to recognize 
the full length protein (α-NHBA FL). 
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4.  Discussion and conclusions 
The meningococcus has successfully evolved to survive in the human nasopharynx, 
which is its only natural habitat. Colonization with this bacterium is frequent 
especially in young adults, however establishing a successful colonization is a very 
challenging step. Within the nasopharynx there are several temperature gradients. For 
example, the temperature on the surface of the anterior nares is around 30°C at the end 
of inspiration, and rises to around 34°C in the posterior nasopharynx and tonsillar 
region (Keck, T. et al. 2000). Both these sites on the mucosal surface are significantly 
cooler than the core body temperature of 37°C, where the bacterium replicates during 
invasive disease. Additionally, fluctuations in the local temperature will be generated 
by acute inflammation, resulting in increased blood flow and systemic illnesses (Eccles, 
R. 2005). Even slight temperature differences have a significant impact on the 
phenotype and proteome of N. meningitidis. Adhesive properties of N. meningitidis 
appear stronger at 32°C in comparison to 37°C and recently another study reported 
also that one of the most induced protein at low temperature resulted to be NHBA 
(Lappann, M. et al. 2016). NHBA is an important virulence factor for N. meningitidis, 
being involved in adhesion (Vacca, I. et al. 2016), biofilm formation (Arenas, J. et al. 
2013) and possibly even in serum resistance through its ability to bind heparin 
(Serruto, D. et al. 2010) (Esposito, V. et al. 2011). It is also a protective antigen able to 
elicit an immune response in preclinical and clinical testing (Serruto, D. et al. 2010), 
therefore understanding the mechanisms that drive NHBA regulation is an important 
goal to better understand N. meningitidis pathogenesis and vaccine induced response.   
We decided to investigate how physiologically relevant temperatures, which mimic the 
different stages of pathogenesis, may affect its expression.  In particular, we found that 
NHBA expression was highly induced at 30°C, similar to what was shown by a 
comparative proteomic study recently reported (Lappann, M. et al. 2016). Although 
expressed in different variants and isoforms, NHBA is a lipoprotein presents in all 
Neisseria species. 
We showed that NHBA expression is at its highest level between 28°C and 30°C, also 
corresponding to higher surface exposure. The regulation in response to temperature is 
driven by a mechanism conserved among all the sixteen different strains tested, 
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irrespective of the clonal complex, the NHBA variant and/or the isoform expressed, 
suggesting the relevance of NHBA regulation for the bacterial physiology.  
Multiple sequence alignment of the intergenic and the 5’TR region of nhba among  8373 
sequences present in the PubMLST database showed a high conservation among 
Neisseria species. As exception, the CREN sequence is present only in hypervirulent 
strains belonging to ST-32 (i.e. MC58). It has been shown that the CREN sequence 
mediates the overexpression of downstream gene in response to cell contact 
(Deghmane, A.E. et al. 2003). When present, the CREN sequence promotes nhba 
expression, again suggesting the importance of a strictly regulated NHBA expression 
during host-pathogen interaction. Nevertheless, the molecular mechanism that drives 
this regulation is not yet fully understood. However, in vitro evidence shows that Hfq 
directly bind RNA-CREN region upstream to nhba (Antunes A., personal 
communications). Hfq has been reported to modulate the half-life of some mRNAs 
directly or by stimulating their poly(A) adenylation (Brennan, R.G. et al. 2007). These 
observations suggested that the 5’UTR can stabilize the messenger against 
ribonucleases. This would be achieved by hairpin structures, RNA binding proteins 
and by sequestered ribosomes, and it can be hypothesized that a putative host factor, 
or a bacterial factor induced by the host, binds to the UTR and thereby controls the 
initiation of translation of the virulence gene. However the mechanism behind cell-
contact upregulation driven by the CREN sequence does not concern the mechanism 
behind thermoregulation, since even strains that lack the CREN sequence show 
fluctuations in NHBA expression in response to temperature. Nevertheless, the nhba 
5’UTR resulted to be a very sensitive region for its expression, anyway. Small deletions 
or even single-base mutations directed to the different putative translational start sites 
identified within this region affect nhba expression even though they do not impair 
thermoregulation. In silico RNA secondary structure predictions revealed that a U-rich 
region identified in the 5’ of the mRNA may base-pair to the RBS, suggesting a possible 
effect on RNA translatability. Synonymous mutations within this tract, where even just 
a single base was replaced, have a dramatic effect on the overall NHBA expression, 
despite no direct effect on thermoregulation was observed. Taking together these 
results highlight the crucial role and the sensitivity of the 5’UTR and the 5’TR for 
NHBA expression.  
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We determined that NHBA expression is growth-phase dependent, with the maximum 
of expression reached during active replication. The growth related mechanism(s), acts 
maybe at transcription level, since the RNA is almost undetectable when stationary 
phase is reached. The reasons why this gene is shut-down at stationary phase have not 
been clarified yet. However, at 30°C the protein resulted to be still abundant even at 
stationary phase, while no bands were visible in extracts from bacteria grown at 37°C 
until stationary phase, suggesting differences in protein stability between 30°C and 
37°C. NHBA expression resulted to be higher at 30°C in each growth phase. These 
observations led to the consideration that the regulations in response to temperature 
changes and growth phase are not related, and moreover underline that nhba is a very 
highly regulated gene with different mechanisms that respond to different conditions 
and stimuli. Nevertheless, by in silico prediction no transcription factor binding sites 
have been found within the nhba intergenic region. 
Our results revealed that multiple molecular mechanisms are responsible for the 
overall regulation of nhba in response to temperature changes. We excluded that the 
genomic context plays a role in this regulation, since replacing the wild type gene in 
another genomic locus does not affect the response to temperature. However, the 
upstream intergenic region per se is not sufficient to drive the response to temperature 
changes, in fact by fusing it to a mCherry reporter gene thermoregulation is lost. 
However, by replacing the wild type promoter with an IPTG-inducible one, differences 
at RNA steady state level are lost, while are still present at protein level even if less 
pronounced than in the wild type strain. This suggest that somehow the wild type 
promoter is requested to drive the regulation in response to temperature detectable at 
RNA level, but moreover highlights that post-transcriptional and post translational 
mechanisms are involved. The upstream regulatory sequences per se are  required but 
not sufficient to obtain the differences observed at RNA steady state level. Instead of a 
direct role in generating differences by alterations in active transcription, the wild type 
upstream sequences seems to be involved somehow in affecting nhba mRNA stability 
and therefore acting at post-transcriptional level. Lapann and colleagues hypothesized, 
but excluded a direct role of σE factor (Lappann, M. et al. 2016). Most likely the 5’ UTR 
and possibly 5’ coding region are required for the formation of secondary structures 
that act as a switch in regulating RNA stability, probably affecting the availability of 
sites recognized by RNA binding proteins or ribosomes recruiting.  
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RNA thermosensors are an energetically efficient strategy that offers rapid responses to 
abrupt changes in the temperature, as seen during the onset of inflammation. RNA 
thermometers respond to the absolute temperature as a physical parameter. They have 
evolved to sense and translate ambient temperature signals to the translation 
machinery in an immediate manner since they control the translation of already 
existing or nascent mRNAs. Therefore, temperature changes have an instantaneous 
effect on the expression of the RNA thermometer-associated transcript and allow a 
rapid and cost-effective response. RNA thermometers are precisely calibrated sensory 
devices that can detect temperature variations on the 1 °C scale (Kortmann, J. et al. 
2012). Typical RNA thermometers control translation initiation by forming a secondary 
structure that entirely or partially includes the 5’UTR of an mRNA, modulating the 
translation efficiency through a thermodynamic-driven mechanism. All three major 
temperature-responsive gene classes — virulence genes, heat shock genes and cold 
shock genes — exploit this concept, making use of RNA thermometers to control 
translation initiation in a temperature-dependent manner (Narberhaus, F. 2010, 
Narberhaus, F. et al. 2006). Usually, the structure traps the RBS and the increase in 
temperature destabilizes it and permits formation of the translation initiation complex. 
Evidences have been reported recently for fHbp and capsule regulation in N. 
meningitidis (Loh, E. et al. 2013, Loh, E. et al. 2016). However, a zipper-like mechanism 
is clearly not compatible with responses that activate gene expression at low 
temperatures.  
Acclimation to low temperatures requires the production of several cold shock proteins 
that counteract membrane rigidification, as well as the formation of stable RNA 
structures that interfere with translation initiation and elongation (Kortmann, J. and 
Narberhaus, F. 2012).  
One of the best characterized regulation in response to cold shock is the massive 
induction of the expression of E.coli cold shock protein A (CspA), an RNA chaperone 
that binds single-stranded RNAs to prevent formation of secondary structures in cold 
temperatures (Jiang, W. et al. 1997). The cspA transcript is very unstable at 37 °C, but is 
dramatically stabilized by global reorganization of its architecture following a 
temperature downshift to 10 °C (Yamanaka, K. et al. 1999). In addition, translational 
control by an in built RNA-based thermosensor enhances cspA expression at low 
temperatures. Deletion analysis of the 160 nucleotide 5ʹ UTR of cspA indicated that 
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cold induction is mainly regulated at the post-transcriptional level by cis-acting 
elements in the transcript (Yamanaka, K. et al. 1999). The ‘cold shock structure’ is more 
efficiently translated and somewhat less susceptible to degradation than the structure 
at 37 °C (Giuliodori, A.M. et al. 2010). The thermosensory region extends far into the 
cspA coding region, and the RNA structure depends on a kinetically driven RNA-
folding process. Sixty nucleotides of the coding region are needed for the decision 
making process and there is only a single hairpin that is shared by the two alternative 
conformations. If and how other cellular factors, for example helicases, influence early 
co-transcriptional events remains to be examined (Kortmann, J. and Narberhaus, F. 
2012). The N. meningitidis homologue for cspA is NMB0838 and its transcript resulted 
to be strongly upregulated at 32°C. NMB1368 is a RNA helicase H belonging to the 
DEAD-box ATP dependent RNA helicases, another family of genes involved in post-
transcriptional changes. We assessed if the deletion of NMB0838 or NMB1368 genes 
would affect the regulation in response to temperature downshift. Mutant strains did 
not show growth or vitality defects, however we excluded a direct role of both genes in 
NHBA thermoregulation, even if slightly decrease in NHBA expression was observed 
in strain grown at 30°C. Nevertheless, we showed that   nhba RNA half-life is directly 
affected by temperature. nhba transcript is highly unstable at 37°C, but is stabilized 
following a temperature downshift to 30°C.  
We hypothesize that low temperature triggers the formation of a secondary structure 
that positively affects the mRNA translatability and somehow makes it less susceptible 
to degradation than the structure at 37°C. We believe that the upstream regulatory 
region is necessary for the formation of these mutually exclusive structures, but it 
seems to act in concert with other regulatory elements. Part of the coding sequence is 
requested too, indicating that the thermosensory region extends far into the nhba 
coding region. Although we cannot exclude a possible role of small regulatory binding 
proteins, which would act in promoting or counteracting the alternative structures 
formation, we have no evidence supporting this hypothesis yet. Therefore, we tend to 
believe that a cis-acting element within the mRNA molecule and/or a trans-acting 
sRNA might be involved in the post-transcriptional regulation of nhba mRNA. 
However, a more detailed characterization would be needed to precisely determine the 
extent of the region and the mechanism involved.  
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Furthermore, we found that NHBA protein is subjected to specific turnover directly 
correlated to temperature changes. At 37°C the protein turnover is very rapid, but 
following temperature downshift to 30°C, the NHBA full length protein showed 
incredibly higher stability. This could also account for the discrepancy between RNA 
and protein expression level found in bacteria grown at 30°C until stationary phase. 
However, we did not investigate what and how is responsible for the differential 
turnover in response to temperature. Taken together, our results indicate that the 
overall regulation of NHBA is a cumulative effect. Multiple molecular mechanisms, 
such as RNA stability/translatability and protein turnover, act in concert to obtain the 
phenotypic differences observed.   
Preliminary results obtained by comparing RNA microarray data and proteomic 
analysis on N. meningitidis strain grown at 30°C and 37°C (data not shown) led us to 
the observation that the effects in response to low temperature are barely detectable at 
RNA level, whereas a more distinct pattern is recognizable at protein level. Indeed, 
temperature downshift promotes not only NHBA higher surface exposure, but also a 
broadly enrichment in outer membrane proteins composition, such as different 
adhesins, siderophore receptor, soluble lytic murein transglycosylase, zinc-manganese 
transport system. This led us to hypothesize the existence of a global regulatory 
network, based on post-transcriptional/post-translational mechanisms. In the light of 
the new findings here reported about NHBA regulation, more in depth studies would 
be needed to address the hypothesis of a global regulatory network that might be used 
by N. meningitidis to fine-tune its surface composition during nasopharynx 
colonization. 
Furthermore, NHBA is one of the three major components of the 4CMenB vaccine 
against serogroup B meningococcus and is a protective antigen that is able to elicit a 
robust immune response. Although NHBA is present in all Neisseria species, we have 
shown that its expression is variable among strains and moreover is affected by 
different factors such as like growth phase and temperature changes. It is therefore 
paramount to understand how different NHBA expression levels, either through strain 
variation or triggered by different growth conditions affect the bacterium’s ability to 
resist immune response. The assay that represents the correlate of protection for 
meningococcal vaccines is the Serum Bactericidal Assay (SBA) and is expected to be 
performed at 37°C. Using an IPTG-inducible test strain as a model it was possible to 
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specifically estimate the influence of different NHBA expression levels on bacterial 
killing during the rSBA without introducing pleotropic alterations caused by different 
incubation temperatures. The correlation of NHBA expression and killing 
susceptibility has an important implication: the higher expression of NHBA during the 
initial steps of transmission/colonization might reflect also higher susceptibility to 
anti-NHBA antibodies in the nasopharynx niche. In the perspective of a broadly 
protective vaccine, NHBA resulted to be an important antigen in terms of cross-
protection, being expressed among all Neisseria species. Furthermore, being highly 
expressed within the nasopharynx during the transmission/colonization steps, NHBA 
could contribute to a decrease in strain carriage and consequently to herd immunity. 
Recently anti-NHBA antibodies have been shown to inhibit adhesion to bronchial 
epithelial cells (Vacca, I. et al. 2016). Therefore, vaccine induced anti-NHBA response 
may be multifunctional, both bactericidal towards NHBA expressing strains, and 
inhibitory towards adhesion and colonization. This is the holy grail for a 
meningococcal vaccine. While only a minority of individuals develop the disease, the 
rate of carriage is considerably high. Therefore meningococcal vaccine strategies 
should aim to counteract invasive disease but also to reduce carriage 
In susceptible non vaccinated individuals, meningococcus can occasionally cross the 
epithelial barrier and enter the bloodstream. During the development of invasive 
disease, N. meningitidis passes from the lower temperatures in the upper airway to the 
core body temperature of 37°C or higher with a febrile response to infection (Cabanac 
M. 1990). Additionally, within the bloodstream meningococcus has to deal with factors 
belonging to the complement cascade. A possible role for NHBA in serum-resistance 
was previously speculated, based on its ability to bind heparin (Esposito, V. et al. 2011, 
Serruto, D. et al. 2010). However, in light of our preliminary findings, it seems that 
NHBA is also involved in the initial response when the bacterium senses and adapts to 
the new invasive environment.  
By mimicking these conditions in vitro, we showed that NHBA expression is also 
influenced by presence of serum in different ways. 
Immediately after serum incubation nhba gene expression is induced, resulting in an 
increase of the NHBA protein as well. Looking at the mRNA induction within a short 
time-course up to 30 minutes, we observed an evolution typically attributable to a 
transcription induction. The initial pulse of transcription has its maximum between 5-
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10 minutes and then it is stabilized to a certain level after 30 minutes of incubation 
(around 2-fold induction respect to T0). It has been shown that NHBA expression is not 
altered following 90 minutes of whole blood incubation (Echenique-Rivera, H. et al. 
2011). We did not look at nhba RNA expression at later time points, however this is not 
in conflict with our observations, where the initial pulse of transcription resulted to be 
transient, as also suggested by protein analysis.     
We also observed that simultaneously to the transcriptional induction, another 
mechanism takes place and affects NHBA protein expression. The full length protein is 
strongly processed, by a protease presents in serum generating an intense lower band 
around 49kDa. It has been shown that NHBA can be processed by the meningococcal 
protease NalP and human lactoferrin (hLf). Cleavage occurs either upstream and 
downstream of the NHBA Arg-rich region resulting in one of two possible cleavage 
fragments termed C2 and C1, respectively (Serruto, D. et al. 2010). Within the blood 
there is abundance of components with proteolytic activity, so it is not surprising to see 
an increase in C-term cleavage. However the component(s) responsible for this 
cleavage within the serum remain to be identified. The protein cleavage immediately 
starts after serum incubation, overlapping to the transcriptional induction for the first 
15-30 minutes, depending on the strain analyzed. Then, the processing results to be 
predominant on the induced expression, which after 30 minutes is become again to the 
basal level and therefore leading to a decrease in the full length protein amount. What 
is responsible for the transcriptional response has not been identified yet, however, it 
seems to be something conserved among different sources of complement, since 
incubation with humans serum, mouse serum or baby rabbit complement leads to 
similar results. Despite we did not observe a direct dose-dependence response in nhba 
transcriptional upregulation, increasing the percentage of serum determines a 
proportional increase in NHBA cleavage, which results more evident in the MC58 
strain. 
Its high susceptibility to cleavage by bacterial and host proteases might let doubt about 
its potential as vaccine target. Monoclonal antibodies targeting the N-term of the 
protein are able to induce in vitro complement bactericidal killing. Functional 
cooperativity between antibodies targeting both the N-terminus and C-terminus of 
NHBA significantly contributes to extend protection against closely related 
phylogenetically MenB strains (Ndoni E, L.S., S Rossi Paccani, D Donnarumma, I 
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Bertoldi, E Bartolini, B Galli, M Bruttini, C Facciotti, P Lo Surdo, N Norais, MM 
Giuliani, V Masignani 2016). Our results confirm the higher functionality of an 
immune response directed towards the full length protein. However, by generating an 
uncleavable strain, we showed that the cleavage does not have a real impact on the 
killing susceptibility. By using an anti-NHBA mouse serum specifically directed 
against to the C terminal portion of the protein, we did not observe a functional 
response. Only minor changes are reported for the uncleavable strain grown at 30°C, 
when incubated with this serum.  
Our results show snapshots of an extremely dynamic equilibrium in which new 
protein production and processing are ongoing. Furthermore, the in vitro correlate of 
protection SBA is a useful but limited tool. The set conditions, such the time of 
incubation, do not really represent the dynamics of the physiological killing process. 
Mathematical modeling of complement cascade activation dynamics highlights that 
after a lag phase of around 10 minutes, the reaction of C3 deposition proceeds 
exponentially until 25-30 minutes of incubation (Korotaevskiy, A.A. et al. 2009, Zewde, 
N. et al. 2016). This is in accordance with our findings about killing susceptibility 
triggered by anti-NHBA sera. The dynamic equilibrium between new protein 
production and processing turns in favor of the full length protein abundance during 
the first 15 minutes of serum incubation, and this time window seems to be sufficient 
to activate the complement cascade and therefore to trigger bacterial killing. 
While antibodies directed against the C-terminus seem to need a cooperation with 
those directed against the N-terminal part to generate a greater functional response, 
the C-terminal region of the protein is very immunogenic in terms of the amount of 
antibodies able to recognize and bind it (Ndoni E, L.S., S Rossi Paccani, D 
Donnarumma, I Bertoldi, E Bartolini, B Galli, M Bruttini, C Facciotti, P Lo Surdo, N 
Norais, MM Giuliani, V Masignani 2016). Therefore, the susceptibility to cleavage 
might belong to a bacterial strategy of immune evasion by displacing antibodies that 
would cooperate and render the killing process even more efficient. On the other hand, 
the C2 fragment, released upon NalP proteolysis, has been shown to alter endothelial 
permeability, contributing to extensive vascular leakage (Casellato, A. et al. 2014). 
Taken together, our results underline the importance of NHBA both as virulence factor 
and as vaccine antigen, shading light into the molecular mechanisms that regulate its 
expression during meningococcal colonization and invasion.  
  
 
65 
 
Collectively, the various gene expression strategies employed by N. meningitidis 
constitute a complex symphony of regulatory mechanisms which enable the bacterium 
to enter the human host, colonize it and escape its defense systems. Consequently, the 
orchestration of these expression strategies must ensure that the correct genes are 
expressed at the appropriate time and in the appropriate locale. Ultimately, 
understanding how these differing transcriptional and posttranscriptional regulatory 
mechanisms function and interact will be invaluable as these various strategies 
underpin the pathogenesis of N. meningitidis. 
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Chapter 2 
 
Comparing different 
antigen delivery systems by 
using NadA as a model 
antigen 
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Immune response and vaccine design 
Vaccine-induced immune effectors are essentially antibodies—produced by B 
lymphocytes—and capable of binding specifically to a toxin or a pathogen (Cooper, 
N.R. et al. 1984). The functionality of the antibodies is determined by antigen 
specificity, avidity and antibody subclass. This determines the ability of antisera to kill 
bacteria directly, but such antibodies may also neutralize toxins in the periphery, they 
may reduce binding or adhesion to susceptible cells/receptors and thus prevent 
colonization if present at sufficiently high titers on mucosal surfaces (Zhang, Q. et al. 
2004). The quality of such antibody response, in terms of avidity, has been identified as 
a determining factor of efficacy. In addition, long-term protection requires the 
generation of immune memory cells capable of rapid and effective reactivation upon 
subsequent microbial exposure. However, the predominant role of B cells in the 
efficacy of current vaccines should not shadow the importance of T cell responses: T 
cells are essential to the induction of high-affinity antibodies and immune memory 
(CA, S. 2013). Antigen binding to naïve B cells initiates their activation and triggers 
their maturation towards the outer T cell zone of secondary lymphoid tissues. 
Interactions among activated B, T and dendritic cells rapidly drives B cell 
differentiation into Ig secreting plasma cells (MacLennan, I.C. et al. 2003). 
Immunoglobulin class-switch recombination from IgM towards IgG, IgA or IgE occurs 
during this differentiation of B cells. Both CD4+ Th1 and Th2 cells exert essential 
helper functions during the extrafollicular differentiation pathway, and the 
engagement of their CD40L molecules with CD40 on B cells may skew class-switch 
recombination into particular Ig classes and subclasses. In rodents, IFN-γ producing 
Th1 T cells promote a switch towards IgG2a, whereas Th2 cells essentially support the 
generation of IgG1 and IgE (via IL-4) and IgG2b and IgG3 (via TGF-β) (Deenick, E.K. et 
al. 2005). The situation is less clear-cut in humans, where IgG1 antibodies frequently 
predominate regardless of the polarization of T cell help. In experimental animal 
models, numerous factors influence the preferential differentiation of CD4+ T cells 
towards the Th1 or Th2 pathways (Swain, S.L. 1995). These determinants include the 
dose of antigen, lower vaccine doses being classically associated with preferential Th1 
responses, and the route of administration, which targets distinct populations of 
dendritic cells. However, the main determinant of CD4+ T cell differentiation is the 
extent and type of dendritic cells activation by the innate system (Kapsenberg, M.L. 
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2003). Meningococcal glycoconjugate vaccine against four of the five disease-associated 
serogroups A, C, W-135 and Y (Gasparini, R. et al. 2011), is an example of overcoming 
the limitations of the related polysaccharide vaccine against serogroup C, which acts in 
a T-independent manner, therefore resulting in lack of immune memory generation. 
This approach is not suitable for vaccine design against N. meningitidis serogroup B 
because of structural similarity of its capsular polysaccharide to the sialic acid found in 
human neural tissue (Finne, J. et al. 1987, Finne, J. et al. 1983). Therefore, novel 
strategies, based on protein vaccines, have been developed to overcome this hurdle. 
The use of chemically detoxified OMV-based vaccines (dOMV) against MenB has been 
explored since the 1970s and public health interventions in countries such as Cuba, 
Norway, and New Zealand (Sierra, G.V. et al. 1991); (Oster, P. et al. 2005) have proven 
the concept of their efficacy. However, a significant limitation of these vaccines is the 
breadth of coverage provided. Minor non-porin proteins in the outer membrane are 
responsible for the cross-protection and different strategies, such as the 4CMenB 
vaccine, use these minor proteins to construct a more universal vaccine. 4CMen has 
demonstrated its safety (Beeretz I., M.S., A. Finn, P. Heath, A. Collinson, G. Bona, S. 
Esposito, P. Dull, E.Ypma, D. Toneatto, A. Kimura, C. Oeser, M. West, T. John, A. J. 
Pollard, and t. E. M. B. V. S. Group 2011, Esposito S., T.V., A. Kimura, E. Ypma, D. 
Toneatto, and P. Dull 2010)  and its efficacy in inducing a protective immune response 
in all age groups against the majority of MenB strains (Findlow, J. et al. 2010, Snape, 
M.D. et al. 2010). Within 4CMenB formulation dOMV are combined with three major 
recombinant antigens. The recombinant antigens induce immune responses to a high 
number of serogroup B strains and the OMV potentiate the immune response to them 
(Acevedo, R. et al. 2014). Novel strategies are envisaged to obtain OMV from 
recombinant N. meningitidis strains, where LPS has been genetically detoxified (lpxL1-
mutants), avoiding the need for detergent extraction (van de Waterbeemd, B. et al. 
2010). In fact, lpxL1 deletion results in a strain with penta-acylated LOS, which has 
reduced endotoxin activity in relation to the wild-type hexa-acylated LOS strain.  
Furthermore, mutant strains with over-expressed protein vaccine antigens, like PorA 
and fHbp, naturally inserted into the membranes have been constructed (Weynants, V. 
et al. 2009) (Koeberling, O. et al. 2011). 
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The Neisserial adhesin A (NadA)  
The Neisserial adhesin A (NadA) is a trimeric autotransporter protein of N. meningitidis 
belonging to the group of oligomeric coiled-coil adhesins. It is formed by three 
identical inter-winded polypeptides organized with a variable N-terminal globular 
portion, called the passenger, protruding outside and comprising the binding site(s) for 
target cell receptors and a conserved C-terminal domain barrel-shaped, that drives the 
self-secretion and anchors the protein onto the bacterial outer membrane. These two 
domains are separated by a flexible coiled-coil stalk comprising a leucine zipper, which 
have a propensity to form trimers. (Hoiczyk, E. et al. 2000, Malito, E. et al. 2014, 
Tavano, R. et al. 2011).  
Through the passenger domain NadA mediates adhesion to human epithelial cells 
(Capecchi, B. et al. 2005), assuming an important role during meningococcal 
colonization of the human upper respiratory tract. However, it is involved in all steps 
of meningococcal physiopathology. In fact, NadA not only promotes invasion of 
human epithelial cells (Capecchi, B. et al. 2005), but it also exerts an immune-
modulatory action on myeloid cells by binding macrophages and dendritic cells. This 
leads to the maturation of dendritic cells as well as the activation and differentiation of 
monocytes into macrophages (Franzoso, S. et al. 2008, Mazzon, C. et al. 2007). 
Furthermore, interacting with the human endothelial receptor LOX-1 it is hypothesized 
to promote the crossing of the blood-brain barrier (Scietti, L. et al. 2016).  
The nadA gene is an independent genetic unit (Comanducci, M. et al. 2002) and is the 
result of an insertion of foreign DNA in the meningococcal genome most likely 
through horizontal gene transfer and subsequent limited evolution to generate five 
variants, each of them including a number of subvariants (Comanducci, M. et al. 2002 
2009, Comanducci, M. et al. 2004).  
NadA is a risk factor for the development of meningococcal disease, being present in 
50% of the disease-associated strains and overrepresented, almost 100%, in 
hypervirulent meningococcal lineages (clonal complexes ST-32, ST-8, ST-11, ST-1157 
and ST-213) (Bambini S., F.J., Klaus H., Taha M.K., Stefanelli P., Caugant D.A., 
Lucidarme J., Gilchrist S., Borrow R., Vogel U. et al. 2011, Comanducci, M. et al. 2004, 
Wang, X. et al. 2011). The nadA gene is carried by about 30% of pathogenic isolates 
collected from patients in 5 European countries and the US (Bambini S., F.J., Klaus H., 
Taha M.K., Stefanelli P., Caugant D.A., Lucidarme J., Gilchrist S., Borrow R., Vogel U. 
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et al. 2011, Wang, X. et al. 2011), whereas only 5% of carriage isolates obtained from 
healthy individuals harbour the gene (Comanducci, M. et al. 2004). Furthermore, nadA 
is absent from N. gonorrhoeae and the commensal N.lactamica and N. cinerea isolates.  
The nadA gene shows growth phase dependent expression, reaching a maximal level in 
the stationary phase (Comanducci, M. et al. 2002, Metruccio, M.M. et al. 2009, Seib, K.L. 
et al. 2010). The expression of nadA is also subjected to phase variation, through the 
presence of a variable length tetranucleotide repeat upstream of its promoter (Martin, 
P. et al. 2003, Metruccio, M.M. et al. 2009). For this reason nadA expression varies both 
between different strains, as well as within a single strain, having variants where 
changes in the repeats number result in promoters with low, medium or high activity 
(Martin, P. et al. 2003, Metruccio, M.M. et al. 2009). However, the major mediator of the 
phase variable expression of nadA is NadR, a MarR-like protein which binds with high 
affinity to two sequences flanking the variable repeat region, acting as repressor 
through sterically hindering RNA polymerase to access to the promoter. Changes in 
the number of repeats affect the ability of NadR to repress the nadA promoter 
(Metruccio, M.M. et al. 2009). As typical for MarR-like proteins, a small molecule 
ligand, 4-hydroxyphenylacetic acid (4HPA), was identified which is able to relieve the 
DNA binding activity of NadR and derepress/induce nadA expression (Metruccio, 
M.M. et al. 2009). 4HPA is a catabolite of aromatic amino acids and is secreted in 
human saliva (Takahama, U. et al. 2002). This metabolite may act as a relevant niche 
signal to meningococci present in the oropharynx, which is bathed in saliva, for the 
modulation of the activity of NadR. 
The proposed model (Figure 2.8) shows that NadR can bind to and repress nadA 
through a looping mechanism, which may result in steric hindrance of RNA 
polymerase access to the promoter, possibly through dimer-dimer interactions on 
multiple binding sites. The interaction of NadR dimers bound at different operators 
might be facilitated by the interplay of the Integration Host Factor (IHF), a histone-like 
protein which was demonstrated to bend DNA upon binding (Swinger, K.K. et al. 
2004). Following the binding of 4HPA or other biologically relevant signals (Figure 8, 
lower panel), the NadR protein can be stabilized in a conformational state which is not 
able to efficiently bind the nadA promoter region, thus causing the induction of 
downstream gene.  
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Figure 2.8 Model of the nadA promoter regulation.  
Two promoter variants with 9 and 8 repeats representing low activity and high activity 
promoter phase variants, respectively, highlighting the ability of NadR to efficiently or less 
efficiently repress the promoters (top panels) and NadR-independent effects on the derepressed 
promoter basal levels possibly due to differential contacts with the α-subunit of RNAP (bottom 
panels) due to different spatial organization of the NadR and RNA polymerase contact points 
resulting from the different number of repeats. (Metruccio, M.M. et al. 2009). 
 
 
NadA is characterized by a high degree of biochemical stability to heat, detergent and 
reduction (Magagnoli, C. et al. 2009). NadA is capable of inducing strong cellular 
immune responses (Bowe, F. et al. 2004), bactericidal antibodies in animal models 
(Bowe, F. et al. 2004, Comanducci, M. et al. 2002, Giuliani, M.M. et al. 2006, Pizza, M. et 
al. 2000) and in humans (Litt, D.J. et al. 2004) as well as the secretion of pro-
inflammatory signals from monocytes and macrophages (Franzoso, S. et al. 2008). 
Therefore it can be used as a model antigen to investigate how different delivery 
systems stimulate the host immune response and helping in next generation vaccines 
design. 
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5.  Results 
5.1.  NadA overexpression on MenB and E.coli nOMV 
In order to produce native outer membrane vesicles (nOMV) carrying high quantities 
of NadA, we overexpressed NadA in MenB and E.coli systems and prepared OMV 
from these strains. Two overexpressing strategies were used for homologous or 
heterologous expression. It has been shown that despite its variable expression levels 
among strains, NadA can be overexpressed in all strains where the gene is present, 
following the removal of its regulator NadR (Fagnocchi, L. et al. 2013). The level of 
expression is critical for the breath of coverage (Fagnocchi, L. et al. 2013). 5/99 is one of 
the higher NadA expressing strains among meningococcal B strains (Metruccio MM, 
2009) and its potential to overexpress the nadA gene is therefore one of the highest. We 
selected this strain to generate nOMV overexpressing NadA following the deletion of 
the nadR gene by replacing it with an antibiotic resistance cassette. Details of the strain 
used are listed in Material and methods section. For heterologous overexpression, the 
BL21ΔtolR E.coli strain was transformed with a plasmid carrying the nadA variant 3 
gene under the control of an IPTG-inducible promoter and used to prepare nOMV 
from the heterologous E.coli system. A 5/99 strain, knocked out for nadA, was used to 
produce nOMV void of NadA as negative control. nOMV were prepared and purified 
as indicated in Material and Methods section, and their physical properties were 
analyzed using immunogold electron microscopy (Figure 5.1), which confirmed the 
presence of NadA on their external surface. The vesicles appeared round, intact and 
with a size distribution ranging from 20 to 100 nm in diameter. In order to characterize 
the proteomic content of nOMV produced by the recombinant over-expressing strains, 
total protein extracts from 0.5 or 1 µg of nOMV were compared to different quantities 
of the recombinant protein, used as titration curve. Proteins were separated on SDS-
PAGE gels and either visualized by Simply BlueTMSafe staining or blotted onto 
nitrocellulose and the protein bands of interest detected using polyclonal mouse sera 
(Figure 5.1 B and C, respectively). nOMV from E.coli and MenB strains both showed a 
band at the NadA expected molecular weight in its trimeric form, visible in the SDS-
PAGE (Figure 5.1 B). The NadA expression was confirmed by Western blot analysis. 
Immunoblotting revealed the presence of some bands in E.coli OMV at a lower 
molecular weight, compatible with the monomeric form of the protein. Furthermore, 
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the NadA overexpression in the meningococcal recombinant strain respect to the wild 
type strain became evident (Figure 5.1 C). Densitometry analysis performed after 
immunoblotting and infrared detection allow us to estimate that the quantity of NadA 
expressed on the nOMV correspond to 20-25% of the total protein content (Figure 5.1 
C). 
 
 
Figure 5.1 Homologous and heterologous expression of NadA on nOMV. (A) 
Immunogold electron microscopy on nOMV produced by meningococcal 5/99 ΔlpxL1 
ΔNadA and 5/99 ΔlpxL1 ΔNadR strains and E.coli BL21ΔTolR_pET21b_NadA strain. 
Total protein extracts from nOMV were performed and separated by SDS-PAGE, using 
the recombinant protein (NadA rP) to set a standard curve. (B) Simply BlueTMSafe 
staining and (C) Western blotting. 
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5.2. Prototype nOMV vaccines elicited high titers of α-NadA antibodies 
CD-1 mice were immunized intra-peritoneally three times with 5 µg of each nOMV or 
20 µg of recombinant form NadA, formulated with aluminum hydroxide to evaluate 
the ability of each vaccine formulation to induce broadly protective α-NadA antibodies 
(Figure 5.2). nOMV prepared from meningococcal NadA knocked-out strain were used 
as a negative internal control.  
 
 
 
Antigen Dose Adjuvant Route 
NadA rP 20 µg 
Alum 
3mg/ml 
IP 
MenB OMV NadA 
KO 
5 µg 
Alum 
3mg/ml 
IP 
MenB OMV 
NadA+ 
5 µg 
Alum 
3mg/ml 
IP 
EColi OMV 
NadA+ 
5 µg 
Alum 
3mg/ml 
IP 
 
 
Figure 5.2 Immunization scheme. Upper panel: five CD-1 mice were immunized intra-
peritoneally (IP) three times, as indicated. Bottom panel: composition of different vaccines 
formulations. 
 
The antibody titers elicited were evaluated by ELISA analysis using post-III 
immunized sera of individual mice (Figure 5.3). All antigen groups elicited antibody 
titers which were significantly higher respect to the negative control, MenB OMV 
NadA KO.  
MenB OMV NadA+ showed slightly lower but less variable response among 
individual mice. However, no significative differences are reported among the three 
groups in terms of geometric mean titres elicited.  
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Figure 5.3 Analysis of sera from mice immunized with nOMV or with recombinant NadA 
protein. IgG α-NadA antibody titers elicited measured by ELISA. Each dot represents an 
individual mouse serum while the line indicates the median value within each immunization 
group.  
  
 
76 
 
5.3.  Evaluation of the bactericidal activity of the antibodies elicited through 
SBA assay 
To estimate the bactericidal activity of the elicited antibodies, mice sera were tested 
against BZ83 meningococcal natural strain. This strain was selected as test strain being 
mismatched for PorA variant, usually the immunodominant antigen of OMV, which 
elicits a PorA specific and not cross response. 
As expected accordingly to ELISA titres, no killing was achieved with the serum 
derived from mice immunized with MenB OMV NadA KO negative control. Instead, a 
great functional response was achieved with sera derived from mice immunized with 
E.coli OMV NadA+ and MenB OMV NadA+ suggesting all bactericidal activity 
measured on the BZ83 test strain is NadA-mediated. The functionality of the antibody 
elicited by OMV formulations is much greater than the ones elicited by the 
recombinant protein (Figure 5.4), indicating that even at lower dose of the antigen, the 
different vaccine formulation improves the functional immune response.  
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Figure 5.4 Serum bactericidal antibody (SBA) titers against BZ83 meningococcal strain. Dots 
represent SBA titers of individual mouse sera against the defined strain. Statistical analysis was 
performed using Kruskal-Wallis multiple comparisons test (ns: not significant; *p<0.05; 
***p<0,001).   
 
Subsequently, IgG subclass (IgG1, IgG2a, IgG2b and IgG3) levels were determined 
(Figure 5.5 A). 
All the vaccine formulations generated antibodies of all IgG subclasses (IgG1, IgG2a, 
IgG2b and IgG3). However, despite the total IgG measured by ELISA resulted to be 
comparable among all the vaccine formulations, immunization with the recombinant 
protein elicited predominantly IgG1. On the other hand, E.coli and MenB OMV NadA+ 
stimulated a significant increase in IgG2a, IgG2b and IgG3 production. It has been 
shown that different mouse IgG subclasses exert different efficiency in functional 
assays (Michaelsen et al 2003), where IgG3 and IgG2b resulted to be the most efficient 
isotypes in SBA performed against meningococcal strains 
(IgG3>>IgG2b>IgG2a>>IgG1). Therefore, the predominance of such IgG subclasses in 
OMV vaccine formulations, may explain the differences observed in the functional 
assay in comparison to the recombinant protein formulation. 
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Furthermore, the IgG2/IgG1 ratio was calculated for all the sera tested, highlighting 
that the magnitude of Th1 response seems to be enhanced in OMV based vaccine 
formulations (Figure 5.5 B). 
 
A 
B 
 
Figure 5.5 IgG subclasses elicited by different vaccine formulations.(A-B) The ratio 
IgG2/IgG1 (lower panel) was calculated considering the sum of both IgG2a and IgG2b. 
Statistical analysis was performed using Two-way ANOVA followed by uncorrected Fisher’s 
LSD multiple comparison test (upper) or Kruskal-Wallis multiple comparison test (lower) (**** 
p<0.0001; *** p<0.001; ** p<0.01; * p<0.05; ns : not significant). 
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5.4. Inhibition of E.coli-NadA var3 adhesion to Chang epithelial cells with 
different sera 
It was previously shown that expression of NadA on the surface of  E.coli (E.coli-NadA) 
promotes bacterial adhesion to Chang epithelial cells (Capecchi, B. et al. 2005). 
Particularly, the N-terminal portion was found to be crucial for the interaction. In order 
to investigate the ability of the above mentioned sera to interfere in the first step of 
bacteria pathogenesis, we decided to pre-incubate E. coli-NadA with the selected sera 
before proceeding with the infection scheme on Chang cell monolayers (Figure 5.6). 
Readout of the infection was provided by the number of cell-associated colony-forming 
units (cfu) from supernatants of cell lysates. Results of these experiments are shown in 
Figure 5.6. The number of cfu obtained in absence of sera (E.coli-NadA) was assigned 
to be 100% of adhesion while the percentage of cfu obtained infecting cells with E.coli-
peT indicates the maximum level of inhibition. These two values were taken as 
references to calculate the magnitude of adhesion after pre-treating with the selected 
sera. Sera raised against nOMV from a MenB strain KO for NadA (α-OMV MenB KO 
NadA), as expected, do not interfere with bacteria adhesion and resulted in 100% 
adhesion. For all the others vaccine formulation there is an inhibitory effect on bacterial 
adhesion at both sera dilutions, with the highest effect elicited by the lowest dilution, 
as expected. Maximum levels of inhibition were obtained with sera raised against 
OMV carrying NadA (α-OMV EColi NadA+ and α-OMV MenB NadA+) regardless of 
the bacteria used to generate OMV.  
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Figure 5.6 Inhibition of NadA-mediated adhesion.  Statistical analysis was performed using 
Two-way ANOVA followed by uncorrected Fisher’s LSD multiple comparison (**** p<0.0001; 
ns: not significant).  
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6.  Discussion and conclusions 
The four component recombinant protein vaccine 4CMenB has demonstrated its safety 
(Beeretz I., M.S., A. Finn, P. Heath, A. Collinson, G. Bona, S. Esposito, P. Dull, E.Ypma, 
D. Toneatto, A. Kimura, C. Oeser, M. West, T. John, A. J. Pollard, and t. E. M. B. V. S. 
Group 2011) (Esposito S., T.V., A. Kimura, E. Ypma, D. Toneatto, and P. Dull 2010) and 
its efficacy in inducing a protective immune response in all age groups against the 
majority of MenB strains (Findlow, J. et al. 2010) (Snape, M.D. et al. 2010).  The 
development of next-generation vaccines requires the combination of diverse 
strategies, such as different delivery systems/adjuvants, to present the antigen in a 
manner that can elicit an adequate and efficient immune response. 
In this work we compared the immune response elicited by recombinant protein and 
nOMV delivery systems, using NadA as model antigen. 
Outer membrane vesicles are very complex supramolecular structures. They contain 
immune stimulators (e.g., LPS, proteins, and DNA) and antigenic molecules that can be 
delivered to immune competent cells of the immune system to trigger maturation as 
well as activation signals. Therefore, OMV have an intrinsic adjuvant effect over 
loaded antigens from bacteria, but also over heterologous antigens that can be 
incorporated or combined in a single formulation. 
Since nOMV generally have high levels of endotoxin activity due to the presence of 
lipooligosaccharide (LOS), the strains used for MenB nOMV-vaccine preparation was 
genetically engineered to reduce/abolish their reactogenicity. The innate human 
immune system senses microbes through a number of receptors that can recognize a 
variety of microbial structure (Manicassamy, S. et al. 2009). LOS, a major component of 
Gram-negative bacteria, is recognized by TLR4 and MD-2 by host innate immune cells 
leading to the production of pro-inflammatory cytokines that initiate and shape the 
adaptive immune response. Lipid A that anchors LOS in the outer membrane of the 
bacterium is primarily responsible for LOS endotoxin activity (Maeshima, N. et al. 
2013, van der Ley, P. et al. 2001). In particular, the specific acylation pattern of the lipid 
A moiety largely determines its biological activity. In order to improve the vaccine’s 
biosafety we directed the integration of an antibiotic resistance cassette into the lpxL1 
gene, thereby inactivating it. The lpxL1 gene deletion alters the chemical composition 
of the lipid A leading to penta- instead hexa-acetylated molecules (Fisseha, M. et al. 
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2005, van der Ley, P. et al. 2001). Even though certain strains of Neisseria can live 
without LOS (Steeghs, L. et al. 1998), we decided to not remove the capacity of the 
bacterium to produce LOS as it has adjuvant properties, stimulating the antibody 
response against outer membrane proteins (OMPs) (van der Ley, P. et al. 2001). In 
particular, the lpxL1 LOS retains adjuvanticity similar to wild-type meningococcal LOS 
while reducing its toxicity as measured by a TNF-alpha induction assay (van der Ley, 
P. et al. 2001). 
We were able to obtain MenB OMV overexpressing NadA by knocking out the nadR 
gene (Fagnocchi, L. et al. 2013), and E.coli OMV overexpressing NadA by using an 
expression plasmid carrying the nadA gene. Both the homologous and the heterologous 
bacterial expression systems showed high level of NadA expressed on the surface. 
Surprisingly, in MenB and E.coli OMV, NadA represents the 20-25% of the total protein 
content within the outer membrane composition. 
20 µg of NadA v3 recombinant protein or 5 µg of OMV-based vaccines were used to 
immunize mice and evaluate the ability to induce bactericidal antibodies. Nevertheless, 
all vaccine formulations containing NadA were able to induce α-NadA antibodies at 
comparable levels. This suggests that the natively expressed NadA in nOMV are 
significantly more immunogenic that the recombinant protein, and/or that the nOMV 
per se have an adjuvant property. 
Moreover, the quality of the antibodies elicited by OMV vaccine formulations was 
superior to that of the antibodies elicited by the recombinant proteins. Even though the 
α-NadA antibody titers were comparable, the antibodies elicited by the vesicles were 
able to elicit a more potent functional response. Remarkably, sera obtained 
immunizing with MenB OMV that do not express NadA, do not show any killing 
activity on BZ83 strain. This observation underlines the specificity and the safety in 
eliciting OMV-driven immune response. 
There could be multiple reasons for higher functional immune responses elicited by an 
antigen delivered on an OMV. 
(I) NadA is characterized by a high degree of biochemical stability to heat, 
detergent and reduction (Magagnoli, C. et al. 2009). Even though, when 
expressed on OMV surface, NadA shows a great stability on its trimeric 
form. OMV overexpressing NadA accurately represent the bacterium 
surface, therefore faithfully presenting the antigen in its natural 
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conformation. The α-NadA antibodies elicited by the OMV vaccines may 
have targeted surface-exposed epitopes better than the antibodies elicited 
by the recombinant NadA vaccine.  
(II) The high density antigenic array presented by a nanoparticle, such an OMV, 
provides a molecular scenario where multiple binding events occur 
simultaneously between the OMV and the host cell B-cell receptors, leading 
to BCR cross-talking and activation of B cells in a T-independent fashion 
which can result in an increased response (CA, S. 2013). This multivalent 
molecular and cellular setting favors the fruitful network of stimulatory 
interactions, as opposed to the weaker effect of monovalent binding 
afforded by single soluble recombinant antigens. Indeed, the high avidity 
for the OMV provided by the multivalent interaction constitutes a critical 
step in the induction of a potent immune reaction (Lopez-Sagaseta, J. et al. 
2016). 
(III) The presence of natural immune potentiators or coadministered adjuvants 
is known to influence the type of immune response. OMV vaccine 
formulations do contain LPS and bacterial DNA, which are agonists for 
TLR4 and TLR9, respectively (Akira, S. et al. 2004). Activation of these 
pathogen recognition receptors stimulates and directs the humoral immune 
response in a T-cell dependent or independent way (Bekeredjian-Ding, I. et 
al. 2009). 
(IV) Finally, OMV phenotypic properties should be taken into account. The 
nanoparticle structures may affect the uptake by different cell types with 
respect to efficiency in uptake and routing within the cells or drain faster 
(unprocessed) to the lymph nodes (Bachmann, M.F. et al. 2010), thereby 
affecting the immune responses induced. 
In immunization studies a complete immunoglobulin subclass profiling, especially 
regarding IgG2b and IgG3, is often absent (Mills, K.H. et al. 1998, Raeven, R.H. et al. 
2015) but should be taken into account for a better understanding of host-pathogen 
interaction and moreover, for vaccine design. Here, we show that different delivery 
systems evoke differentially flavored immune response. We found that the differences 
in functionality were associated with distinct antibody subclass repertoires elicited by 
the different vaccine formulations. OMV were able to elicit high titers of IgG2a, IgG2b 
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and IgG3, besides IgG1, while, the recombinant proteins elicited high titers of mostly 
IgG1.  
The human IgG subclasses are known to differ in their ability to activate complement 
mediated responses. Specifically, IgG1 and IgG3 antibodies activate complement 
efficiently, whereas IgG2 antibodies are effective mainly at high epitope density 
(Michaelsen, T.E. et al. 1991). IgG3 antibodies show the highest affinity in complement 
activation and the relative balance of the IgG subclasses in any immune complex helps 
to determine the strength of the inflammatory processes that follows (Michaelsen, T.E. 
et al. 1991). Alternatively, murine IgG2 exhibit the most complement activation, and 
the increases in the elicitation of IgG2 subclasses could explain the higher functional 
responses of the OMV immunizations in mouse sera. The formation of antibody-
producing B-cells can occur either through a T-cell dependent or independent way. In 
the case of T-cell involvement, the type of cytokines secreted, e.g. IFNγ, IL-4, IL-5, and 
IL-17, determines the IgG subclass production by B-cells (Mitsdoerffer, M. et al. 2010, 
Raeven, R.H. et al. 2015, Stevens, T.L. et al. 1988). In mice, Th1 type responses promote 
the production of IgG2a, whereas Th2 responses stimulate the formation of IgG1 
(Germann, T. et al. 1995). In addition, production of IgG2b seems to be linked to a Th17 
type response (Mitsdoerffer, M. et al. 2010). Whereas all types of T cell help stimulate 
the secretion of IgG3 (Germann, T. et al. 1995, Stevens, T.L. et al. 1988), the highest 
IgG3 formation is achieved by T-cell independent antibody responses by B-cells 
(Quintana, F.J. et al. 2008).  
Therefore, the presence of LPS and DNA in OMV vaccine formulations might partially 
explain the different subclass responses.   
This indicates that the sum of all interactions within and between activated pathways 
determines the environmental conditions in which the B-cells reside, and consequently 
the outcome of the humoral response.  
NadA mediates adhesion to human epithelial cells (Capecchi, B. et al. 2005), assuming 
an important role during meningococcal colonization of the human upper respiratory 
tract and moreover its expression is induced in vivo by signals present in the saliva 
(Fagnocchi, L. et al. 2013). Additional evidence of the crucial role of NadA head 
domain in meningococcus pathogenesis are provided by Malito and colleagues 
(Malito, E. et al. 2014) that mapped the epitope of the neutralizing bactericidal mAb 
33E8 on this portion of the adhesin. Here, we showed that all the sera raised against 
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NadA are also able to interfere with adhesion. However, maximum levels of inhibition 
were obtained with sera raised against OMV carrying NadA, regardless of the bacteria 
used to generate OMV.  
Overall, these data suggest that the use of OMV as a vehicle probably results in a better 
exposure of the antigen to the immune system. Conformational epitopes important to 
mediate host-pathogen interaction can be better recognized, therefore resulting in a 
stronger inhibition of NadA-mediate adhesion. 
Taken together all these data support the potential of OMV as vaccine platform, and 
also the great potential of NadA as a model antigen. 
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7.  Materials and Methods 
7.1.  Bacterial strains and culture conditions 
All the strains used in this study are listed in Table 8.1 (Appendix section). N. 
meningitidis strains were routinely grown on chocolate agar (Biomerieaux), Gonococcus 
(GC) agar (Difco) supplemented with Kellogg's supplement I, or on Mueller-Hinton 
(MH) agar (Difco) at 30°C or 37°C (as specified for single experiments), 5% CO2 
overnight. Liquid cultures were grown under the same conditions in GC with 
Kellogg’s supplement I or in Mueller Hinton (MH) broth plus 0.25% glucose. Colonies 
from overnight growth were used to inoculate 7 ml cultures at an optical density at 
600 nm (OD600) of ∼0.05. The cultures were incubated at 37°C with shaking until early 
exponential (OD600 ∼0.25) or mid-exponential phase (OD600 ∼0.5) or as specified in the 
individual experiments. When required isopropyl β-D-1-thiogalactopyranoside (IPTG) 
(Sigma) was added to culture medium at the indicated final concentrations.  
Strains were stocked in GC medium with 15% glycerol and were stored at −80°C.  
Escherichia coli DH5-α (Hanahan, D. 1983), HK100 (Klock, H.E. et al. 2009) and 
BL21(DE3) ΔTolR (Berlanda Scorza et al., 2008) strains were grown in Lysogeny broth 
(LB) and when required, ampicillin, kanamycin and chloramphenicol were added to 
achieve final concentrations of 100, 25 and 10 μg ml-1 respectively.  
 
7.2.  Generation of plasmids and N. meningitidis new recombinant strains 
All recombinant strains and plasmids used in this study are listed in Table 8.1, while all 
the oligonucleotides used are listed in Table 8.2 (Appendix section). DNA 
manipulations were carried out routinely as described for standard laboratory 
methods (Sambrook J, 1989). Generation of all deletion mutants (Δnhba), MC58Δnhba-
Cnhba and MC58Δnhba-Ptac_nhba strains were obtained as described in (Serruto, D. et 
al. 2010). Generation of 5/99 recombinant strains were obtained as described in 
(Fagnocchi, L. et al. 2012) and (Koeberling, O. et al. 2008). To obtain the 
pCOM_14aa_mCherry plasmid, used to generate the MC58Δnhba-Pwt_mCherry strain, 
polymerase incomplete primer extension (PIPE) PCR (Klock HE, 2009) was performed. 
The coding sequence of the mCherry gene optimized for Neisseria (Invitrogen) was 
amplified with mCherryFw   and mCherryRev   primers. The pCOM_nhba plasmid was 
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used as template to amplify the backbone with divergent primers: Vector Fw, that 
maps in the chloramphenicol resistance cassette, and Pwt_14aa Rev that allow the 
amplification of the intergenic region upstream to nhba, including its own promoter 
and the first 14 amino acids of the coding sequence.  NmmCh_Nde Fw and 
NmmCh_Nsi Rev primers were used to amplify the mCherry sequence (Invitrogen). 
Afterwards, the amplicon was subcloned on pCOM-PInd vector using the restriction 
sites included within the sequence.  
Upstream and downstream flanking regions that drive the homologous recombination 
to obtain NMB0838 or NMB1368 deletion, were amplified from MC58 genomic DNA 
through fusion PCR and then cloned into pGEM-Teasy plasmid. The chloramphenicol 
resistance cassette was therefore inserted by using the BamHI site placed in between of 
them. Site-directed mutagenesis was performed on pCOM_Cnhba plasmid to generate 
mutants Mut_1-Mut_7, by using pairs of primers indicated in Table 8.2.  Due to the 
extent of the mutation needed to obtain the MC58_ΔTSFAmRR, two round of site-
directed mutagenesis were performed. The pBS_nhba plasmid was used as template 
and amplified by using mRR Fw/Rev primers to generate pBS_mRR plasmid. Then, 
the pBS_mRR plasmid was amplified by using ΔTSFA Fw/Rev primers to generate the 
pBS_ΔTSFAmRR plasmid. All PCR amplifications were performed using the KAPA 
Hi-FI polymerase (KAPA Biosystem), following manifacturer’s instructions. The 
correct nucleotide sequence of each plasmid was confirmed by DNA sequencing. Prior 
to transformation into N. meningitidis, plasmids were linearized by restriction digestion 
using SpeI (New England Biolabs) following the manufacturer’s instructions. For 
transformation of naturally competent N. meningitidis, five to ten freshly grown 
overnight colonies were re-suspended in 30 µl of GC medium and spotted onto GC 
plates. 1-10 µg of linearized plasmid DNA was added, allowed to dry and incubated 
for 5-6 h at 37°C. Transformants were then selected on GC plates containing 
erythromycin (5 µg ml-1), kanamycin (150 µg ml-1) or chloramphenicol (5 µg ml-1) after 
overnight incubation at 37°C. Single colonies were re-streaked on selective media and 
genomic DNA purified by crude lysis after overnight incubation at 37°C. Single 
colonies were re-suspended in 100 µl of distilled water, boiled for 10 min and 
centrifuged in a bench top centrifuge for 5 min at 8000 × g. One to three microliters of 
the sample were used as template for PCR analysis to check the correct insertion of the 
resistance marker by a double homologous recombination. 
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7.3.  Polyacrylamide gel electrophoresis and Western blotting 
N. meningitidis colonies from overnight plate cultures were re-suspended in PBS to an 
OD600 of 0.5. One milliliter of the resuspension was centrifuged for 5 min at 15000 × g 
and the pellet re-suspended in 100 µl in 2X SDS-PAGE loading buffer (50 mM Tris Cl 
[pH 6.8], 2.5% (w/v) SDS, 0.1% (w/v) bromophenol blue, 10% (v/v) glycerol, 5% (v/v) 
β-mercaptoethanol, 50 mM dithiothreitol [DTT]) (Oriente, F. et al. 2010). For liquid 
culture, 1 ml of each sample was collected and the concentration normalized in 2x SDS-
PAGE loading buffer respect to the relative optical density at 600 nm. Protein extracts 
were separated by SDS-PAGE on NuPAGE® Novex® 4-12% Bis-Tris Protein Gels in 
MES 1X (Life Technologies) and transferred onto nitrocellulose membrane using an 
iBlot Dry Blotting System (Invitrogen). Membranes were blocked for 2 h at room 
temperature with PBS with 0.05% (v/v) Tween 20 (Sigma) and 10% (w/v) powdered 
milk (Sigma) and then incubated for 60 min at room temperature with the specific 
primary antibodies diluted in PBS + 0.05% (v/v) Tween 20 (Sigma) and 3% (w/v) 
powdered milk (Sigma). A horseradish peroxidase-conjugated anti-mouse IgG 
antibody and the Western Lightning ECL (Perkin Elmer) were used according to the 
manufacturer’s instructions and the densitometry quantification was performed by 
using the ImageJ 1.6 software. 
 
7.4.  Quantitative real-time PCR (qRT-PCR) experiments. 
Bacterial cultures were grown in 7 ml of liquid medium to OD600 as specified for the 
individual experiments. Three ml of the culture were then poured onto 3 ml of frozen 
medium to immediately chill the culture and stop transcriptional changes. Cells were 
then harvested by centrifugation at 3400 × g for 10 min. Total RNA was isolated using 
an RNeasy Mini kit (Qiagen) as described by the manufacturer. A second step of 
DNase treatment was performed using RQ1 RNase-free DNase (Promega), for one 
hour at 37°C and purified with the RNeasy Mini kit. RNA was quantified using a 
Nanodrop 1000 spectrophotometer and its overall quality was assessed by running 
samples on a 1% agarose gel. 2 μg of total RNAs were reverse-transcribed using 
random hexamer primers and SuperScript® II RT (ThermoFisher), following 
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manufacturer’s instructions. As negative controls, all RNA samples were also 
incubated without reverse transcriptase. 
Quantitative real time-PCR was performed in triplicate per sample in a 25 μl reaction 
volumes using Platinum® SYBR® Green qPCR SuperMix-UDG with Rox 
(ThermoFisher) according to the manufacturer’s instructions and containing 2.5 ng of 
cDNA, and 0.4 μM of gene-specific primers (See Table 8.2). Amplification and 
detection of specific products were performed with a Mx3000P Real-Time PCR system 
(Stratagene) using the following procedure: 95ºC for 10 min, followed by 40 cycles of 
95ºC for 30 s, 55ºC for 30 s and 72ºC for 30 s then ending with a dissociation curve 
analysis. The 16S RNA gene was used as the endogenous reference control and the 
relative transcript change was determined using the 2-ΔΔCt relative quantification 
method (Livak, K.J. et al. 2001). Two-way ANOVA was used to calculate statistical 
significance and significance levels are indicated on the respective figures (* p < 0.05; 
** p <0.01; *** p< 0.001). 
 
7.5.  Flow cytometry  
Strains were grown in GC or MHB broth until an OD600 of 0.25 or 0.5, collected by 
centrifugation (8000 × g for 5 min), incubated for 1 h at room temperature with 
secondary antibody alone, mouse monoclonal antibodies or mouse polyclonal sera 
diluted to specific concentrations indicated in the respective experiments in PBS 
containing 0.1% (w/v) BSA. The cells were then incubated for 1 h at room temperature 
with a secondary rabbit anti-mouse immunoglobulin G (whole molecule) FITC-
conjugated (Sigma) and then incubated for 2 h at room temperature in PBS containing 
0.5% (w/v) paraformaldehyde (PFA). After a final washing step, cells were re-
suspended in 100 µl of PBS and 7 µl of each sample were plated on MH plates and 
incubated overnight at 37°C to confirm inactivation of the bacteria. All data were 
collected using a BD FACS CANTO II (BD Bioscience) by acquiring 10,000 events, and 
data were analyzed using the Flow-Jo software (v.8.6, TreeStar Inc.). 
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7.6.  Serum Bactericidal Assay (SBA) 
Serum bactericidal activity against N. meningitidis strains was evaluated as previously 
described (Giuliani, M.M. et al. 2005) with pooled baby rabbit serum (Cederlane) used 
as the complement source (rSBA). Bacteria were grown in Mueller Hinton broth (MH), 
plus 0.25% (w/v) glucose and the indicated concentration of isopropyl β-D-1-
thiogalactopyranoside (IPTG) (Sigma) at 37°C (or 30°C as specified for respective 
experiments) with shaking until early exponential phase (OD600 of ∼0.25) and then 
diluted in Dulbecco’s saline phosphate buffer (Sigma) with 0.1% (w/v) glucose and 
1% (w/v) BSA (Bovine Serum Albumin) to approximately 105 CFU/ml. The incubation 
with 25% of baby rabbit complement with or without polyclonal mouse sera at 
different dilutions was performed at 37°C (or 30°C as specified for respective 
experiments) with shaking, for 60 min. Serum bactericidal titers were defined as the 
serum dilution resulting in a at least 50% decrease in the CFU/ml after 60 min of 
incubation of bacteria with the reaction mixture, compared to the control CFU/ml at 
time zero.  
 
7.7.  RNA stability assay 
The N. meningitidis NGH38 wild type strain was grown at 30°C or 37°C until mid-
exponential phase and active transcription was stopped by adding rifampicin 
(200 ug ml-1). Each culture was kept at 30°C or 37°C for 15 min by using a pre-warmed 
water bath. Three ml of culture were collected at different timepoints (1,2 and  5 
minutes) and processed for total RNA isolation. Whole cell protein extracts were taken 
at different time points and analyzed by Western blotting. 
 
7.8.  Protein stability assay 
The N. meningitidis MC58 wild type strain was grown at 30°C or 37°C until mid-
exponential phase and active translation was stopped by adding spectinomycin 
(150 ug ml-1). Each culture was split in two equal parts and incubated at either  30°C or 
37°C for 2 h. Whole cell protein extracts were taken at different time points and 
analyzed by western blotting. 
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7.9. nOMV vaccine preparation  
The nOMV vaccines were prepared growing 5/99 derivative strains in MCDMI -
Meningitidis Chemical Define Medium I- medium. The N. meningitidis strains were 
first pre-inoculated into 7 mL of MCDMI at an OD600 ranging from 0.15-0.2 and 
incubated  at 37°C at 180 rpm until mid-exponential phase (=0.8-0.9 OD). Due to the 
stable nature of the chromosomal integration, no antibiotics were added to the growth 
medium. The mid-exponential pre- cultures were inoculated into 50 mL medium in 
250 mL baffled flasks and grown over night (16-18 h) until late stationary phase at 37°C 
and 180 rpm. BL21(DE3) ΔTolR strains were pre-cultured overday in 7 ml of LB 
medium supplemented with 100 µg/ml of ampicillin. The cultures were diluted 1:100 
in 50 ml of HTMC liquid medium and incubated overnight at 30°C, 5% CO2, 160 rpm. 
Bacteria were centrifuged at 3400 × g for 15 min, resuspended into 60 ml of fresh 
HTMC broth supplemented with 1mM IPTG and incubated for 3 h at 37°C, 5% CO2, 
160 rpm. The bacterial cells were pelleted by centrifugation for 30 min at 3400 × g and 
4°C and the culture supernatants filtered (pore size 0.22 µm). nOMV were collected 
from the filtered supernatants by ultracentrifugation for 2 h at 96000 × g, 4°C and an 
additional washing step with 1X PBS was performed. The nOMV pellets were re-
suspended depending on their size in 50-200 µl of 1X PBS. Protein concentrations were 
determined by a microtitter plate-based Lowry protein assay (DC protein assay, 
BioRad).  
Table 7.1 Growth medium MCDMI (Meningitidis Chemical Define Medium I) recipe 
Component g l-1 mM 
Soy peptone (Bacto Soytone)* 15 NA 
Sodium chloride  5.8 99.2 
Potassium sulfate  1 5.7 
Potassium phosphate dibasic  4 23.0 
L-glutamic acid  5 34.0 
L-arginine  0.3 1.7 
L-serine  0.5 4.8 
L-cysteine  0.23 1.9 
Magnesium chloride hexahydrate  0.41 2.0 
Calcium chloride**  0.021 0.189 
Ferric citrate***  0.002 0.008 
Glycerol**** 5 NA 
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* Neisseria meningitidis will not grow in all Soypeptone extracts! Use Bacto Soytone, 
Catalog number 243620, BD Biosciences.  
** CaCl2 stock solution, 10 g l-1 (0. M), 2.1 ml 
*** Ferric citrate stock solution, 0.5 g l-1, 4.0 ml 
**** Glycerol serves to stabilize OMVs 
 
Table 7.2 Growth medium HTMC recipe 
Component g l-1 
Glycerol 15 g/l 
Yeast Extract 30 g/l 
MgSO4 7H2O 0.5 g/l 
K2HPO4 20 g/l 
KH2PO4 5 g/l 
*pH 7.35 with KOH 1M 
 
 
7.10. Transmission Electron Microscopy 
Negative Stain Electron microscopy 
Purified OMVs were diluted to 0.03 mg/ml in PBS, pH 8 buffer and 5 µl were loaded 
for 3 minutes onto a 300 mesh carbon/ formvar coated copper grid (Agar Scientific). 
Blotted the excess, the grids were negatively stained with 1% aqueous Uranyl Acetate 
for 45 seconds and anlyzed using a Tecnai G2 Spirit transmission electron microscope 
operating at 100 kV equipped with a Morada CCD camera. The micrographs were 
acquired at a magnification of 87000 X. 
Immunogold electron microscopy 
Purified OMVs were diluted to 0.03 mg/ml in PBS pH 8 buffer and 5 µl were loaded 
for 3 minutes onto a 300 mesh carbon/ formvar coated nickel grids (Agar Scientific). 
Blotted the excess, the grids were firstly blocked with 0.5%PBS-BSA and then 
incubated with primary anti-NadA mouse polyclonal serum (diluted 1:4000 in PBS 
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with 0.5% bovine serum albumin) for 1 h. Grids were washed several times and 
incubated with 5- or 10-nm gold-labeled anti-mouse secondary antibody (diluted 
1:2000 in in PBS with 0.5% bovine serum albumin) for 1 h. After several washes with 
distilled water the grids were negatively stained in 1% uranyl acetate and 
observed  using a TEM FEI Tecnai G2 spirit microscope operating at 100kV and 
equipped with an 2K × 4K CCD Olympus SIS Morada camera (Olympus, Shinjuku, 
Tokyo, Japan). Images were acquired and processed using iTem (OSIS, Olympus, 
Shinjuku, Tokyo, Japan) software. 
nOMV were fixed overnight in 2.5% glutaraldehyde in PBS and then washed and re-
suspended in the same buffer. A drop of suspension was placed on formvar/carbon-
coated grids, and nOMV were adsorbed for 5 min. Grids were then washed with 
distilled water and blotted with a filter paper. For negative staining, grids were treated 
with 2% uranyl acetate for 1 min, air-dried and viewed with a Joel JEM 1200EXII 
electron microscope operating at 80 kV. 
 
7.11. Mice immunizations  
Groups of five between 6- to 8-week old female CD-1 mice (Charles River) were 
immunized intra-peritoneally (IP). For each injection, the mice received a total dose of 
5 µg of nOMV vaccines or 20 µg of NadA recombinant proteins. The nOMV or the 
recombinant protein vaccines were absorbed with aluminum hydroxide (Alum, 
3 mg ml-1) and administered in three doses at day 1, 21 and 35. Blood was taken at day 
0, 20, 34 for further analysis and bleed out was performed on day 49.  The experiment 
complied with the relevant guidelines of Italy and the institutional policies of GSK 
Vaccines. 
 
7.12. IgG antibody titers elicited against NadA 
Serum antibody titers against NadA were measured by ELISA, which was performed 
as described elsewhere (Welsch, J.A. et al. 2003). Microtitter plates were coated 
overnight at 4°C with 0.015 µM of purified NadA recombinant protein variant 3. Plates 
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were incubated with single mice sera followed by alkaline phosphatase-conjugated 
anti-mouse antibodies. After addition of p-nitrophenyl phosphate, optical density was 
analyzed using a plate reader at a dual wavelength of 405/620-650 nm. Antibody titers 
were quantified via interpolation against a reference standard curve. 
To quantify the IgG subclasses, the microtitter plates were coated overnight at 4°C with 
1.0 µg ml-1 of purified NadA recombinant protein variant 3, following the protocol 
described above. Finally, the antibody titers were quantified as the dilution of serum 
that gave an absorbance of 0.4 OD. 
 
7.13. Inhibition of the binding assay 
Escherichia coli BL21(DE3)T1R (New England Biolabs) was used to express full-length 
NadA variant 3 following transformation with pET21-nadA, as previously described 
(Capecchi, B. et al. 2005), or  the empty vector as control. E. coli was cultured at 37°C in 
Luria–Bertani (LB) broth supplemented with 100 μg/mL of ampicillin. Surface protein 
expression for full-length NadA was achieved without addition of Isopropil-β-D-1-
tiogalattopiranoside (IPTG) exploiting the expression due to the leakage in the 
induction system. Chang epithelial cells (Wong-Kilbourne derivative, clone 1-5c-4, 
human conjunctiva, ATCC CCL-20.2) were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with antibiotics and 10% heat-inactivated fetal bovine 
serum (iFBS). Cells were grown at 37°C in 5% CO2. 
Chang cells were seeded in a 24 well plate (1.5 x 105 cells/well) in antibiotics-free 
medium with 1% iFBS (Infection Medium) and were allowed to grow for 24 h.  For 
adhesion analysis, E.coli wild type or expressing NadA were added at a multiplicity of 
infection (MOI) of 100 and allowed to adhere for 3 h at 37°C and 5% CO2. Unattached 
E. coli were removed by extensive washing, and bacteria were counted using serial 
dilution plating. For inhibition of binding assay, recombinant E. coli wild type or 
expressing NadA were pre-incubated in rotation with diluited sera (1:20; 1:200; 1:2000) 
or infection medium alone for 1 hour at 4°C before addition to the cells. 
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8. Appendix 
Table 8.1 Plasmids and strains used in this study  
Plasmid or strain Description 
Antibiotic 
resistance
a
 
Reference 
or source 
Plasmids    
pBluescript (pBS) Cloning vector Amp Stratagene 
pBS-UDgna2132 Plasmid for deletion of 
N.meningitidis nhba gene by 
homologous recombination 
Amp, Ery (Serruto, D. 
et al. 2010) 
pBS_nhba pBS derivative for in locus 
complementation of nhba gene 
(MC58 sequence) 
Amp, Cml (Vacca, I. et 
al. 2016) 
pComCmr-Pind Plasmid for allelic replacement at 
chromosomal location between ORFs 
NMB1428 and NMB1429 and 
inducible expression under control of 
Ptac promoter and lacI repressor 
Amp, Cml (Ieva, R. et 
al. 2005) 
pCOM-Cnhba Plasmid for complementation of 
nhba null mutant. Derivative of 
pComCmr-Pind containing a copy of 
nhba (MC58 sequence)  
Amp, Kan (Serruto, D. 
et al. 2010) 
pCOM-Ptac_nhba Plasmid for complementation of 
nhba null mutant. Derivative of 
pComCmr-Pind containing a copy of 
nhba (MC58 sequence) 
Amp, Cml (Serruto, D. 
et al. 2010) 
pBS_14aa_mCherry Derivative of pBS_nhba. Construct 
for complementation of the mCherry 
reporter gene under the control of 
nhba intergenic region 
Amp, Clm This study 
pCOM_14aa_mCherry Construct for complementation of the 
mCherry reporter gene under the 
control of nhba intergenic region. 
Derivative of pComCmr-Pind 
Amp, Clm This study 
pCOM_Ptac_mCherry Construct for complementation of the 
mCherry reporter gene under the 
control of an IPTG-inducible Ptac 
promoter. Derivative of pComCmr-
Pind 
Amp, Clm This study 
pUClpxL1kanR 
Construct for generating 
knockout of lpxL1 gene 
Kan (Koeberling
, O. et al. 
2008) 
pET21b E.coli expression vector Amp Novagen 
pET21b_NadAv3 
pET21b derivative. Construct for 
NadAv3 expression 
Amp (Capecchi, 
B. et al. 
2005) 
pD1843ko::AmpR, pGEM-T (Invitrogen) derivative. Amp, Clm (Fagnocchi, 
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CmR Construct for generating 
knockout of the NadR gene 
L. et al. 
2012) 
pDNadA::EryR 
pBS derivative. Construct for 
generating knockout of the NadA 
gene 
Ery (Fagnocchi, 
L. et al. 
2012) 
N.meningitidis strains    
M11205 Clinical isolate   
M11205 Δnhba nhba null mutant of M11205,  Ery This study 
M11822 Clinical isolate   
M11822 Δnhba nhba null mutant of M11822,  Ery This study 
NGH38 Clinical isolate   
NGH38 Δnhba nhba null mutant of NGH38,  Ery This study 
MC58 Laboratory-adapted N.meningitidis 
reference strain 
  
MC58 Δnhba nhba null mutant of MC58,  Ery (Serruto, D. 
et al. 2010) 
M10935 Clinical isolate   
M10935 Δnhba nhba null mutant of M10935,  Ery This study 
M14933 Clinical isolate   
M14933 Δnhba nhba null mutant of M14933,  Ery This study 
M10713 Clinical isolate   
M10713 Δnhba nhba null mutant of M10713,  Ery This study 
M03279 Clinical isolate   
M03279 Δnhba nhba null mutant of M03279,  Ery This study 
N16/97 Clinical isolate   
N16/07 Δnhba nhba null mutant of N16/07,  Ery This study 
M11204 Clinical isolate   
M11204 Δnhba nhba null mutant of M11204,  Ery This study 
M10282 Clinical isolate   
M10282 Δnhba nhba null mutant of M10282,  Ery This study 
M07-0240679 Clinical isolate   
M07-0240679 Δnhba nhba null mutant of M07-0240679,  Ery This study 
M11719 Clinical isolate   
M11719 Δnhba nhba null mutant of M11719,  Ery This study 
M16453 Clinical isolate   
M16453 Δnhba nhba null mutant of M16453,  Ery This study 
M18070 Clinical isolate   
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M18070 Δnhba nhba null mutant of M18070,  Ery This study 
8047 Clinical isolate   
MC58 Δnhba-C_nhba Complemented nhba mutant of 
MC58 
Ery, Kan (Serruto, D. 
et al. 2010) 
MC58 Δnhba-
Ptac_nhba 
Complemented mutant of MC58 
expressing nhba (MC58 sequence) 
under the control of an IPTG-
inducible Ptac promoter 
Ery, Clm (Serruto, D. 
et al. 2010) 
MC58 Δnhba-
14aa_mCherry 
Complemented mutant of MC58 
expressing mCherry reporter gene 
under the control of nhba intergenic 
region (MC58 sequence) 
Ery, Clm This study 
MC58 Δnhba-
Ptac_mCherry 
Complemented mutant of MC58 
expressing mCherry reporter gene 
under the control of an IPTG-
inducible Ptac promoter 
Ery, Clm This study 
5/99 Clinical isolate   
5/99 ΔlpxL1 lpxL1 null mutant of 5/99 Kan 
 
This study 
5/99 ΔlpxL1 ΔNadA Derivative of 5/99 ΔlpxL1; NadA 
null mutant 
Kan, Ery This study 
5/99 ΔlpxL1 Derivative of 5/99 ΔlpxL1; NadR 
null mutant 
Kan, Cml This study 
E.coli strains    
DH5-α  supE44 hsdR17 recA1 endA1 
gyrA96 thi-1 relA1 
 (Hanahan, 
D. 1983) 
BL21(DE3) ΔTolR  
hsdS gal (λcIts857 ind1 Sam7 nin-
5 lacUV5-T7 gene 1) 
 (Berlanda 
Scorza, F. et 
al. 2008) 
BL21_NadAv3 BL21(DE3) derivative strain 
carrying the pET21b_NadAv3 
plasmid for expression of NadA 
Amp This study 
a
Amp, ampicillin; Kan, kanamycin, Ery, erythromycin; Clm, chloramphenicol
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Table 8.2  Oligonucleotides used in this study 
Oligonucleotide Sequencea 
Restriction 
site 
Application 
Reference or 
source 
NMB2132RT-F GGCTTGTATTTTTGCCCTTTC 
 qRT-PCR nhba gene This study 
NMB2132RT-R GCATCTTCCTTTGCCTCTGT 
 
mCherry_RT1 fw GCTCAGTTTCAGGTAGTCCG 
 qRT-PCR mCherry gene This study 
mCherry_RT1 REV AGCCCTCAATTCATGTACGG 
 
pRTNM16sII.F1 GTGGGGAATTTTGGACAATG 
 qRT-PCR 16s gene This study 
pRTNM16sII.R1 CAACAGCCTTTTCTTCCCTG 
 
mCherry Fw  TCCAAAGGCGAGGAAGATAAC 
 Generation of Pwt_mCherry 
fusion: insert PCR to amplify 
the mCherry gene optimized 
for N. meningitidis 
This study 
mCherry Rev CACGGATCCCTGCAGTTATTTGTACAGTTCGTCCATG 
 
CmR Fw CTGCAGGGATCCGTGATATAG 
 Generation of Pwt_mCherry 
fusion: vector PCR on 
pBS_nhba background 
This study 
Pwt_14aa Rev CTTCCTCGCCTTTGGAGGCAAAAATACAAGCCATTGC 
 
Insert Fw  CGAAAGTGGGAATCTAGACATTATCGGCGTGATTCAG 
 Subcloning of Pwt_mCherry 
fusion into pCOM plasmid 
This study 
Insert Rev  GAGCATAAAATTTTAGTAACCTATGTTTTTATTCAGCAAGTCTTGTAATTC 
 
Vector Fw  GAATTACAAGACTTGCTGAATAAAAACATAGGTTACTAAAATTTTATGCTC 
 
Subcloning of Pwt_mCherry This study 
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Vector Rev  CTGAATCACGCCGATAATGTCTAGATTCCCACTTTCG 
 
fusion into pCOM plasmid 
NmmCh_NdeI Fw GAAACACATATGATGGTGTCCAAAGGCGAG NdeI 
Cloning mCherry gene into 
pCOM_Ptac plasmid 
This study 
NmmCh_NsiI Rev GTGTCAATGCATTTATTTGTACAGTTCGTCCATGCC NsiI 
Mut_1_Fw GAAATACGATGAAGGAGATGATGTTTAAACGCAGCG  
 Deletion of putative TSS This study 
Mut_1_Rev CGCTGCGTTTAAACATCATCTCCTTCATCGTATTTC 
 
Mut_2_Fw GAAATACGATGAAGGAGATGTTTAAACGCAGCG  
 Deletion of putative TSSs This study 
Mut_2_Rev CGCTGCGTTTAAACATCTCCTTCATCGTATTTC 
 
Mut_3_Fw ACCAAAAAGGAAATACGCTGAAGGAGATGATGATGTT 
 Mutation of putative TSS This study 
Mut_3_Rev AACATCATCATCTCCTTCAGCGTATTTCCTTTTTGGT 
 
Mut_4_Fw AAAGGAAATACGATGAAGGAGCTGCTGCTGTTTAAACGCAGCGTAATCGCA 
 
Mutation of putative TSSs This study 
Mut_4_Rev TGCGATTACGCTGCGTTTAAACAGCAGCAGCTCCTTCATCGTATTTCCTTT 
 
Mut_5_Fw GCAATGGCTTGTATCTTTGCCCTTTCAGCCTGC 
 Site-directed mutagenesis of 
T-rich region 
This study 
Mut_5_Rev GCAGGCTGAAAGGGCAAAGATACAAGCCATTGC 
 
Mut_6_Fw CAATGGCTTGTATTTTCGCCCTTTCAGCCTGCG 
 Site-directed mutagenesis of 
T-rich region 
This study 
Mut_6_Rev CGCAGGCTGAAAGGGCGAAAATACAAGCCATTG 
 
Mut_7_Fw CGCAATGGCTTGTATCTTCGCCCTTTCAGCCTGCG 
 Site-directed mutagenesis of 
T-rich region 
This study 
Mut_7_Rev CGCAGGCTGAAAGGGCGAAGATACAAGCCATTGCG 
 
NMB1368_FwEst TCGTATTCCTGAAGGTGGATTCGATCGCCGTAAACATCG 
 
Deletion of NMB1368 This study 
NMB1368_RevInt_BamHI GTGCTGAAACATTGCAAAAAGGATCCCTATCCTTGGAAGACAACAA BamHI 
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NMB1368_FwInt_BamHI TTGTTGTCTTCCAAGGATAGGGATCCTTTTTGCAATGTTTCAGCAC BamHi 
NMB1368_RevEst ACATTGTTATGTTGCCGTTTGATTTTCAGACGGCATTTTGTTT 
 
NMB0838_FwEst TGCATGACTTGTTGTTGTTTGGTTTGGGCAATATCGCGCGTGT 
 
Deletion of NMB0838 This study 
NMB0838_RevInt_BamHI AAATATACATTTGACCGTAGGATCCATCCTGCTTAACCGTCTTTTTA BamHI 
NMB0838_FwInt_BamHI TAAAAAGACGGTTAAGCAGGATGGATCCTACGGTCAAATGTATATTT BamHI 
NMB0838_RevEst GTGGAAAACGGCGTGATTGCCTACCCCGTCCACGAGATTA 
 
2132 mRR1  GCGCGATTTGGGGGTTCTGCAGGGTCGGGGGGGTCGCTTCC 
 Mutation of Arg-rich motif in 
Gly stretch 
(Serruto, D. 
et al. 2010) 2133 mRR2 GGAAGCGACCCCCCCGACCCTGCAGAACCCCCAAATCGCGC 
 
ΔTFSAmRR Fw TCTTTTATAAACCTAAACCCCGATTTAGGCGTTCTGCACGGT 
 Deletion of NalP target 
domain sequence  
This study 
ΔTFSAmRR Rev ACCGTGCAGAACGCCTAAATCGGGGTTTAGGTTTATAAAAGA 
 
LpxL1_ext fw GGCGGTTTGAGTTAGGAAGC 
 Check integration in LpxL1 
locus 
This study 
LpxL1_ext rev CGTTTGAAAACAAAGTGGCAAAGGC 
 
Kan Int_fw ATTATCGAGCTGTATGCGGAGTG 
 Check integration in LpxL1 
locus 
This study 
Kan Int_rev GCAATCCACATCGGCCAGAT 
 
ΔNadRExt_Fw  CAATATGCCCGTGCAGGT 
 
check ΔNadR deletion This study 
ΔNadRInt_Rev  ATCGAGGATGCGTTGAACTC 
 
ΔNadRInt_Fw  AAG GGA TTA CAT CGG CAG 
 
ΔNadRExt_Rev  GGG ACA GTT TAG CCG AGA 
 
ΔNadAExt_Fw  CGATATGGACGTCGACGTCCTCGAT 
 
check ΔNadA deletion This study 
ΔNadAInt_Rev  GTGGTTTCATCCAGAGCGGCATCAG 
 
ΔNadAInt_Fw  TCGGTTCAATGTAACGGCTGCAGT 
 
ΔNadAExt_Rev  TTGACGGAAATCGGCATTACGGGC 
 
ΔNMB0838_Fwext TATGCACCATCGCCCGTTGCAT 
 check ΔNMB0838 deletion This study 
ΔNMB0838_RevExt ACAACCTGTATTTGAACCATACGCACGA 
 
  
 
101 
 
ΔNMB0838_RevInt_CmrR TTACGTTTGGGAAGTATTATGAGGA 
 
check ΔNMB0838 and 
ΔNMB1368 deletion 
This study 
ΔNMB0838_FwInt_CmrR CTATCCACTATATCATAAATCTATCCAC 
 
check ΔNMB0838 and 
ΔNMB1368 deletion 
This study 
ΔNMB1368_FwExt TTCTCGTACTGCTGCAAACCTT 
 check ΔNMB1368 deletion This study 
ΔNMB1368_RevExt AAATTCACACGGGCAGGCAACCAA 
 
pRTNM4 GTTTTGACAGCGTGTCCG 
  
This study 
pRTNM5 CAGGTTCTCAAGGACAGGGC 
  
This study 
pRTNM6 CGCCTTTACAGTGGGTCAAC 
  
This study 
pRTNM7 GTTTACCTGCCTGCGTGA 
  
This study 
pRTNM8 GAAGAGTTCAGCGCAGTTTC 
  
This study 
pRTNM9 CTGCTGATTCCTTTGGC 
  
This study 
pRTNM10 CCTGTCCTTGAGAACCTG 
  
This study 
pRTNM11 GTTGACCCACTGTAAAGGC 
 
Sequencing of NHBA 
mutants 
This study 
pRTNM12 CGAAGGGCATACGATCC 
  
This study 
pRTNM13 ATTACGGTTGACTTCGCCAC 
  
This study 
pRTNM14 AATCACGCCGATAATGAAGC 
  
This study 
pRTNM15 AAATCGCTGCTGATGAACCT 
  
This study 
pRTNM16 GTAACGTCCGAACCGTGATT 
  
This study 
pRTNM17 
CTTCGACCGACGTTTTGTTT 
 
Sequencing of NHBA 
mutants (intergenic region) 
This study 
pRTNM18 AAAATATGCCGTCTGAACGC 
  
This study 
pRTNM19 GCGTTCAGACGGCATATTTT 
  
This study 
pRTNM20 CAGGCTGAAAGGGCAAAA 
  
This study 
pRTNM21 TATTTTTGCCCTTTCAGCCT 
 
Sequencing of NHBA 
mutants 
This study 
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pRTNM22 
CGCCATTGCCTGTATTTTCT 
 
Sequencing of NHBA 
mutants (intergenic region) 
This study 
pRTNM23 ATACGCTGATTGTCGATGGG 
  
This study 
pRTNM24 ATTTTTCCGCCCCGTAAGT 
 
Sequencing of NHBA 
mutants 
This study 
COMseq TTTGAAAATGAGATTGAGC 
 
Sequencing of NHBA 
mutants 
This study 
ComCFw CCTCGAGCCGCTGACCGAAGG 
 
Complementation check in 
the COM region (upstream 
recombination) 
This study 
ComRev ACCGGCATCGGCAACTACAC 
 
Complementation check in 
the COM region 
(downstream recombination) 
This study 
CM-UP-C GGTCGAAATACTCTTTTCGTGTCC   
Complementation check in 
the COM region (upstream 
recombination) 
This study 
a
Underlined letters indicate restriction enzyme sites, bold letters indicate nucleotide mutationa 
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